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Mg   Milligram 
µg   Microgram 
mm   Millimeter 
0
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Fig   Figure 
UV-VIS  Ultraviolet and visible spectroscopy 
IR   Infrared spectroscopy 
1
HNMR  Nuclear Magnetic Resonance 
Std   Standard 
TLC   Thin layer chromatography 
KBr   Potassium bromide 
IC   Inhibitory concentration 
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DMSO  Dimethyl sulfoxide 
 
 
 
ABBREVIATIONS 
 
ABSTRACT 
A series of Schiff bases of flavones have been synthesized by both conventional and microwave 
irradiation method, purified and characterized on the basis of spectral data (IR, 
1
HNMR and 
Mass spectra). The title compounds were screened for their preliminary anti-microbial activity 
against bacteria (Gram positive and Gram negative strains) and fungi by disc diffusion method. 
The minimum inhibitory concentration (MIC) was determined by 2-fold dilution technique. 
Majority of the tested compounds showed mild to significant preliminary anti-microbial activity 
at 100µg/disc when compared to standard drugs ciprofloxacin and Clotrimazole at 5µg/disc 
concentration level. Among the synthesized compounds DPN 07, DPN 08, DPN 11 was found to 
be moderate activity against most of the screened bacteria and fungi. MIC results indicate that 
the compound DPN 07, DPN 08 have anti-bacterial activity at 6.25µg/ml and 12.5µg/ml 
concentrations level.  The entire screened compound exhibited in vitro anti-malarial activity 
against Plasmodium falciparum, in which Compounds DPN 08, DPN 11& DPN 12 exhibited 
potent activity when compared with standard. The DPPH, FRAP and ABTS in-vitro anti-oxidant 
methods result of the synthesized compound review that high reactivity of hydroxyl substituent’s 
influence the anti -oxidant activity. None of the tested compounds show in-vitro anti-cancer 
activity.  Compound DPN 07, DPN 08, DPN 11 and DPN12 were found to be more potent 
compound, so this can be used as lead for further studies. 
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1.1.1 CHEMISTRY: 
Flavonoids based on the backbone of 2-phenylchromen-4-one (2-phenyl-1-
benzopyran-4-one) (Fig 1.1). Flavones are phenols that are widely present in the flowers, 
leaves and fruit tissues of living plants as flavonoid glycosides. The aglycones present in 
some flavones are poisonous to plants and can be separated only from dead timber. 
Deriving their name from their yellow color, and have dual roles. While sometimes they 
draw pollinating insects with their color, in other times their toxic property enable them 
act as repellents to insects that harm the plants. At the same time, tests have shown that 
flavanoids are also capable of regulating the growth of the plants.  
 
Flavonoids are either bitter or sweet in taste and recent chemical tests have proved 
that minor altercations in their cell structure can change their taste from bitter to sweet or 
the other way around. This is significant, as it shows that the bitter and sweet taste 
receptors in our tongue are situated close to each other and also analogous in structure. 
 
Fig 1.1 
Flavonoids are one of the most abundant natural product groups occurring in the 
plant kingdom. Although the term flavonoids has been interchangeably used by many, 
including researchers. Flavonoids generally have a common C5-C3-C6 flavone skeleton in 
which the three carbon bridge between the phenyl group is usually enclosed with oxygen 
.based on the degree of unsaturation and oxidation of the three carbon segment (c -ring), 
flavonoids are divided into several sub classes most of the flavones reported in the 
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literature are glycosides of a relatively small number of flavonoid aglycones, which are 
generally water soluble and accumulated in the vacuoles of plant cells.  
The structural features of the B –ring and the hydroxylation and glycosylation 
patterns on all A, B, and C rings of the flavones skeleton have made flavonoids one of the 
largest and diverse phytochemical group. 
 A significant role that has been under active research in recent years is their 
possible health beneficial effect to humans. Flavonoids have been found to posses potent 
anti oxidant activities. Increasing evidence from epidemiological studies suggests that 
diets high in flavonoids are contributing significantly to lower risks of cardio vascular 
diseases and cancer in humans, for this reason, both healths‘ Canada and the US food and 
drug administration have allowed health claims for fruits and vegetables consumption 
and lowered risks of heart disease. 
Flavones are mainly found in cereals and herbs. In the West, the estimated daily 
intake of flavones is in the range 20-50 mg per day 
(1)
. In recent years, scientific and 
public interest in flavones has grown enormously due to their putative beneficial effects 
against atherosclerosis, osteoporosis, diabetes mellitus and certain cancers 
(2)
. Flavones 
intake in the form of dietary supplements and plant extracts has been steadily increasing. 
Flavones have effects on CYP (P450) activity 
(3)
 which are enzymes that 
metabolize most drugs in the body. By these observations many research shows 
synthesized flavonoids by following synthetic route formed, 
 Baker-Venkataraman rearrangement (4) 
 Allan-Robinson reaction(5) 
 Auwers synthesis(6) 
 Algar-Flynn-Oyamada reaction(7) 
 
 
 
 
 
\ 
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Baker–Venkataraman rearrangement  
 
 
Scheme 1.1 
In the first step, 2-hydroxyacetophenone or its derivative is treated with an 
aromatic acid chloride to form an aryl ester, which in the second step, is reacted with a 
base. The ester is transformed into diaryl 1, 3-diketone through an intramolecular 
rearrangement. Treatment of the latter with an acid leads to the formation of the 
corresponding flavone. (Scheme 1.1) A variety of 2-hydroxyaryl alkyl ketones and a 
number of aromatic acid chlorides work very well. Thus a large number of substituted 
flavones are accessible through this simple synthetic procedure. 
 
This rearrangement reaction proceeds via enolate formation followed by acyl 
transfer with a base being a catalyst, it attacks hydrogen atom in Acetophenone and an 
enolate is formed. Then, the enolate group attacks the carbon in the phenol ester to form a 
cyclic alkoxide. Finally, it opens up a phenolate which is reprocessed by acid to undergo 
protonation (Scheme 1.2) 
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.  
Scheme 1.2 
From the above view point, we here on report the synthesis of flavones by 
Baker–Venkataraman rearrangement method & Microwave irradiation technique 
and their anti Microbial, anti malarial, anti oxidant, anti cancer activity. 
 
1.1.2 SCHIFF BASE 
A Schiff base is a compound with a functional group that contains a carbon-
nitrogen double bond with the nitrogen atom connected to an aryl or alkyl group, not 
hydrogen 
(8)
. Schiff bases in a broad sense have the general formula R
1
R
2
C=NR
3
, where 
R is an organic side chain. In this definition, Schiff base is synonymous with azomethine. 
Some restrict the term to the secondary aldimines (azomethines where the carbon is 
connected to a hydrogen atom), thus with the general formula RCH=NR'
(9)
.  
The chain on the nitrogen makes the Schiff base a stable imine. A Schiff base 
derived from aniline, where R
3
 is a phenyl or a substituted phenyl, can be called an anil 
(10)
.
 
N
C
R R2
R3
 
Schiff bases can be synthesized from an aromatic amine and a carbonyl 
compound by nucleophic addition forming a hemiaminal, followed by a dehydration to 
generate an imine. 
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1.2 Micro wave irradiation technique 
Environmental pressure to reduce waste and reuse materials has driven studies 
into ‗Green‘ chemistry. Chemical and pharmaceutical industries are always under 
pressure to develop more environmentally friendly organic reaction methodologies using 
nonhazardous catalysis. Microwave irradiation is used for a variety of organic reactions 
due to short reaction time, cleaner reactions, easier work-up and better yield. Thus the 
microwave oven procedure is now well established in MORE chemistry 
(11)
. More 
recently, the emphasis has shifted in favour of microwaves-assisted methods under 
solvent-free conditions, providing an opportunity to work in open vessels, thus avoiding 
the risk of the development of high pressure. Inorganic solid support organic 
transformations are gaining much attention due to simplified product isolation, mild 
reaction conditions, high selectivity etc. Solvent free microwave assisted chemical 
reactions in combination of solid supported reagents, were used to carry out a wide range 
of reaction in shorter time as compare to other conventional reaction methods 
(12)
. The 
use of solvent free conditions with heterogeneous catalysts represents one of the more 
powerful green chemical procedures 
(13)
. 
Microwave irradiation has been successfully applied in organic chemistry. 
Spectacular accelerations, higher yields under milder reaction conditions and higher 
product purities have all been reported. Indeed, a number of authors have described 
success in reactions that do not occur by conventional heating and even modifications of 
selectivity (chemoregio- and stereo selectivity). The effect of microwave irradiation in 
organic synthesis is a combination of thermal effects, arising from the heating rate, 
superheating or ―hot spots‖ and the selective absorption of radiation by polar substances. 
Such phenomena are not usually accessible by classical heating and the existence of non-
thermal effects of highly polarizing radiation—the ―specific microwave effect‖—is still a 
controversial topic. The thermal effects and the current state of non-thermal microwave 
effects are effectively used in organic synthesis.      
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MW heating has gained popularity in the last decades as it remarkably accelerates 
a wide variety of reactions and minimizes thermal decomposition of the products. Since 
the initial work of Gedye and Giguere, a rapidly increasing number of reports and 
reviews have been published demonstrating the importance of such methodology. 
However, to the best of our knowledge, the potentially of this method has not been 
exploited yet for the type of reactions of interest in this case .The use of MW irradiation 
offers many advantages over conventional heating: it remarkably decreases reaction 
times, requires less solvent, thus facilitating reaction workups and increases yields. 
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1.4 ANTI MICROBIAL
 (14)
 
1.4.1 Antibacterial 
Synthetic antibacterial compounds are divided into two major classes: topical 
agents and systemic agents. The topical agents are termed disinfectants, antiseptics, and 
preservatives, depending on how they are used. Antiseptics and disinfectants differ from 
systemic agents in that they show little selective toxicity between the microbes and the 
host. Furthermore, most of them do not aid wound healing and may even impair it. 
Nevertheless, there are indispensable uses for disinfectants in hospital sanitation, 
including sterilization of surgical instruments, public health methods, and in the home. 
Antiseptics have important applications in the preoperative preparation of both surgeons 
and patients. They also are used in treating local infections caused by microorganisms 
refractive to systemic antimicrobial agents. 
1.4.1a. Mechanisms of bacterial resistance 
The outer membrane of Gram-negative bacteria is composed of lipopolysaccharide, 
proteins, and lipids
 (15)
. It presents a barrier to many chemical agents, including 
quaternary ammonium compounds and triphenylmethane dyes. In contrast, the 
cytoplasmic membrane of Gram-positive bacteria, excepting spores and mycobacteria, 
has greater permeability to most agents
 (16)
. Spores have a special coat and/or cortex that 
may not be permeable to hydrogen peroxide and chlorine disinfectants. Bacterial cells 
may also have efflux mechanisms that extrude agents such as quaternary ammonium 
compounds, dyes, and mercury compounds from their interiors
 (17)
. 
1.4.1b. Systemic synthetic antibacterial 
Prontosil rubrum
 (18)
, a sulfonamido-azo dye, was the first clinically useful systemic 
antibacterial agent to be discovered. This discovery was done in the early 1930s and the 
development of sulfonamides and sulfones as a class of antibacterial agents. Their broad 
antimicrobial spectrum provided, for the first time, drugs for the cure and prevention of a 
variety of bacterial infections; their widespread clinical use brought about a sharp decline 
in morbidity and mortality of treatable infectious diseases, and thus proved of great 
medical and public health importance. Recognition of the inhibition of the action of 
sulphonamides by extracts which was &own to be attributed to the presence of p-
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aminobenzoic acid (PABA), required in folate biosynthesis, was the first clear 
demonstration of metabolites antagonism as a mechanism of drug action; this provided 
the long sought after mechanistic basis for drug action. 
 
1.4.2 Antifungal
 (19)
 
The first antifungal discovered in 1939 was griseofulvin. The introduction of 
griseofulvin was followed in 1960 by that of amphotericin B, which is still the ―gold 
standard‖ for the treatment of severe systemic mycoses. 
Fungal infection are caused by Eukaryotic organisms and for that reason they 
generally present more difficult therapeutic problems than do bacterial infections. The 
fungal cell wall may be considered to be a prime target for selectively toxic antifungal 
agent because of its chitin structure, absent from human cells. Day by day number of 
antifungal agent are preparing and against fungi. 
Of the five fundamental Kingdoms of Life, the Kingdom Fungi is arguably the 
most diverse and prevalent. Unlike the kingdom Monera (containing bacteria), fungi are 
eukaryotic organisms whose cellular fundions consequently resemble those of plants and 
animals more closely. Thus the issue of selectivity predominates in the quest for safe and 
effective chemotherapeutic remedies for diseases caused by fungi. As with all 
chemotherapy, there is a risk-reward ratio to be taken into account; in the context of 
fungal infections, this ratio may vary greatly, from minor irritations such as athlete's foot 
to life-threatening systemic infections such as those caused by Aspergillus fumigatus. 
This addresses medicinal aspects of the treatment of fungal diseases of all types, but 
because most recent research has been directed toward the treatment of systemic 
infections, emphasis is placed on this aspect. 
Antibiotic resistance 
Antibiotic resistance is a type of drug resistance where a microorganism is able to 
survive exposure to an antibiotic. Many antibiotic resistance genes reside on plasmids, 
facilitating their transfer. If a bacterium carries several resistance genes, it is called 
multiresistant or, informally, a superbug or super bacterium. The primary cause of 
antibiotic resistance is antibiotic use both within medicine and veterinary medicine. The 
greater the duration of exposure, the greater the risk of the development of resistance 
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irrespective of the severity of the need for antibiotics. As resistance becomes more 
common there becomes a greater need for alternative treatments. However despite a push 
for new antibiotic therapies there has been a continued decline in the number of newly 
approved drugs. Antibiotic resistance therefore poses a significant problem. 
 
1.5 MALARIA: 
MALARIA is a mosquito borne infectious disease caused by a eukaryotic protest 
of genus Plasmodium. It is widespread in tropical and subtropical regions, Asia, Africa 
and parts of America .It is the most serious and widespread parasitic disease because of 
its prevalence, virulence and drug resistance, having an overwhelming impact on public 
health in developing regions of the world, and most dreadful protozoal diseases affecting 
man each year, more than 500 million people are infected and nearly two million people 
die of malaria, the majority of who are young children.  Malaria is commonly associated 
with poverty, and can indeed be a cause of poverty and a major hindrance to economic 
development. 
Malarial Parasite: 
(20, 21)
 
Casual organism for malaria belongs to genus Plasmodium. Five species of the 
Plasmodium parasite can infect humans: the most serious forms of the disease are caused 
by Plasmodium falciparum. Malaria caused by Plasmodium vivax, Plasmodium ovale 
and Plasmodium malaria are milder and is not generally fatal. A fifth 
species, Plasmodium knowlesi, is a zoonosis that causes malaria in macaques can also 
infect humans. Plasmodium falciparum is the main cause of severe clinical malaria and 
Endemic map indicates that. P.falciparum account for 95% of the malaria infections and 
is also responsible for about 90% of the deaths from malaria.  
Malaria parasites contain apicoplasts, that play a crucial role in various aspects of 
parasite metabolism e.g. fatty acid bio-synthesis, 466 proteins have been found to be 
produced by apicoplast and these are now being looked at as possible targets for novel 
anti-malarial drugs. 
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Mosquito vectors and the Plasmodium life cycle: 
(22, 23, 24)
 
The life cycle of the malarial parasite (Plasmodium) is complicated and involves 
two hosts, humans and Anopheles mosquitoes. The parasite's primary (definitive) hosts 
and transmission vectors are female mosquitoes of the Anopheles genus, while humans 
and other vertebrates are secondary hosts. Young mosquitoes first ingest the malaria 
parasite by feeding on an infected human carrier and the infected Anopheles mosquitoes 
carry Plasmodium sporozoites in their salivary gland. Once ingested the 
parasite gametocytes taken up in the blood will further differentiate into male or female 
gametes and then fuse in the mosquito gut. This produces an ookinete that penetrates the 
gut lining and produces an oocyst in the gut wall. When the oocyst ruptures, it releases 
sporozoites that migrate through the mosquito's body to the salivary glands, where they 
are then ready to infect a new human host. Only female mosquitoes transmit the disease. 
Malaria parasites can also be transmitted by blood transfusions, although this is rare. 
Malaria in humans develops via two phases: an exoerythrocytic and an 
erythrocytic phase. The exoerythrocytic phase involves infection of the hepatic system, or 
liver, whereas the erythrocytic phase involves infection of the erythrocytes, or red blood 
cells. When an infected mosquito pierces a person's skin to take a blood 
meal, sporozoites in the mosquito's saliva enter the bloodstream and migrate to the liver. 
Once in the liver, these organisms differentiate to yield thousands of merozoites.  
Following rupture of their host cells, escape into the blood and infect red blood cells, thus 
beginning the erythrocytic stage of the life cycle. The parasite escapes from the liver 
undetected by wrapping itself in the cell membrane of the infected host liver cell. Within 
the red blood cells, the parasites multiply further, again asexually, periodically breaking 
out of their hosts to invade fresh red blood cells. Several such amplification cycles occur. 
Thus, classical descriptions of waves of fever arise from simultaneous waves of 
merozoites escaping and infecting red blood cells. 
  Some P.vivax, P. ovale  sporozoites do not immediately develop into 
exoerythrocytic-phase merozoites, but instead produce hypnozoites that remain dormant 
for periods ranging from several months (6–12 months is typical) to as long as three 
years. After a period of dormancy, they reactivate and produce merozoites. Hypnozoites 
are responsible for long incubation and late relapses in these two species of malaria. 
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   The parasite is relatively protected from attack by the body's immune 
system because for most of its human life cycle it resides within the liver and blood cells 
and is relatively invisible to immune surveillance. However, circulating infected blood 
cells are destroyed in the spleen. To avoid this fate, the P. falciparum parasite displays 
adhesive proteins on the surface of the infected blood cells, causing the blood cells to 
stick to the walls of small blood vessels, thereby sequestering the parasite from passage 
through the general circulation and the spleen. This "stickiness" is the main factor giving 
rise to hemorrhagic complications of malaria. High endothelial venules (the smallest 
branches of the circulatory system) can be blocked by the attachment of masses of these 
infected red blood cells. The blockage of these vessels causes symptoms such as in 
placental and cerebral malaria. In cerebral malaria the sequestrated red blood cells can 
breach the blood brain barrier possibly leading to coma.  
Although the red blood cell surface adhesive proteins (called PfEMP1, 
for Plasmodium falciparum erythrocyte membrane protein 1) are exposed to the immune 
system, they do not serve as good immune targets, because of their extreme diversity; 
there are at least 60 variations of the protein within a single parasite and effectively 
limitless versions within parasite populations. The parasite switches between broad 
repertoires of PfEMP1 surface proteins, thus staying one step ahead of the pursuing 
immune system. 
Some merozoites turn into male and female gametocytes. Fertilization and sexual 
recombination of the parasite occurs in the mosquito's gut, thereby defining the mosquito 
as the definitive host of the disease. New sporozoites develop and travel to the mosquito's 
salivary gland, completing the cycle.  
 
SYMPTOMS OF MALARIA: 
(25)
 
Symptoms of malaria include fever, shivering, arthralgia (joint pain), anemia, 
vomiting, hemoglobinuria, retinal damage, and convulsions. The classic symptom of 
malaria is cyclical fever every six hours, occurring every two days in P. vivax and P. 
ovale infections, while every three days for P. malaria. P. falciparum can have recurrent 
fever every 36–48 hours or a less pronounced and almost continuous fever. Children with 
malaria frequently exhibit abnormal posturing and cognitive impairments. It causes 
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widespread anemia . Cerebral malaria is associated with retinal whitening, which may be 
a useful clinical sign in distinguishing malaria from other causes of fever. Severe malaria 
is almost exclusively caused by P. falciparum infection, and usually arises 6–14 days 
after infection. Consequences of severe malaria include coma, splenomegaly, severe 
headache, cerebral ischemia, hepatomegaly, hypoglycemia, hemoglobinuria with renal 
failure. Severe malaria can progress extremely rapidly and cause death within hours or 
days. In the most severe cases of the disease, fatality rates can exceed 20%, even with 
intensive care and treatment.  
Diagnosis:
 (26)
 
   The diagnosis of malaria is confirmed by the blood tests which can be divided into 
microscopic and non-microscopic tests. 
 A microscopic test involves staining and direct visualization of the parasite under 
the microscope. 
 Peripheral Smear study- MP test                                                                                 
 Quantitative Buffy coat (QBC) test 
 A non-Microscopic test involves the identification of the parasitic antigen or 
the anti plasmodial antibodies or the parasitic metabolic products. 
 Rapid Diagnostic tests (RDTS) 
 
1.6.1 ANTIOXIDANT  
The adverse effects of oxidative stress on human health have become a serious 
issue. The World Health Organization (WHO) has estimated that 80% of the earth‘s 
inhabitants rely on traditional medicine for their primary health care needs, and most of 
this therapy involves the use of plant extracts and their active components. Under stress, 
our bodies produce more reactive oxygen species (ROS) (e.g., superoxide anion 
radicals, hydroxyl radicals and hydrogen peroxide) than enzymatic antioxidants (e.g., 
superoxide dismutase glutathione peroxidase (GPx), and catalase) and non-enzymatic 
antioxidants (e.g., ascorbic acid (vitamin C), tocopherol (vitamin E), glutathione, 
carotenoids, and flavonoids). This imbalance leads to cell damage
 (27)
 and health 
problems
 (28)
.  
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A lack of antioxidants, which can quench the reactive free radicals, facilitates 
the development of degenerative diseases
 (29)
, including cardiovascular diseases, cancers
 
(30), neurodegenerative diseases, Alzheimer‘s disease (31) and inflammatory diseases (32). 
One solution to this problem is to supplement the diet with antioxidant compounds that 
are contained in natural plant sources
 (33)
. These natural plant antioxidants can therefore 
serve as a type of preventive medicine. Recent reports indicate that there is an inverse 
relationship between the dietary intake of antioxidant-rich foods and the incidence of 
human disease
 (34)
. However, synthetic antioxidants, such as butylated hydroxytoluene 
(BHT) and butylated hydroxyanisole (BHA), have been widely used as antioxidants in 
the food industry and may be responsible for liver damage and carcinogenesis
 (35)
. 
Antioxidants including phenolic compounds (e.g., flavonoids, phenolic acids and 
tannins) have diverse biological effects such as anti-inflammatory, anti-carcinogenic and 
anti-atherosclerotic effects as a result of their antioxidant activity
 (36)
. 
An antioxidant is a molecule capable of inhibiting the oxidation of other 
molecules. Oxidation is a chemical reaction that transfers electrons from a substance to 
an oxidizing agent. Oxidation reactions can produce free radicals. In turn, these radicals 
can start chain reactions that damage cells. Antioxidants terminate these chain reactions 
by removing free radical intermediates, and inhibit other oxidation reactions. They do this 
by being oxidized themselves, so antioxidants are often reducing agents such as thiols, 
ascorbic acid or polyphenols 
(37)
.  
Although oxidation reactions are crucial for life, they can also be damaging; 
hence, plants and animals maintain complex systems of multiple types of antioxidants, 
such as glutathione, vitamin C, and vitamin E as well as enzymes such as catalase, 
superoxide dismutase and various peroxidases. Low levels of antioxidants, or inhibition 
of the antioxidant enzymes, cause oxidative stress and may damage or kill cells. As 
oxidative stress might be an important part of many human diseases, the use of 
antioxidants in pharmacology is intensively studied, particularly as treatments for stroke 
and neurodegenerative diseases. However, it is unknown whether oxidative stress is the 
cause or the consequence of disease. 
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Reactive oxygen species (ROS), capable of causing damage to DNA, has been 
associated with carcinogenesis, coronary heart disease, and many other health problems 
related to advancing age
 (38)
. In low concentrations, synthetic antioxidants are also in use 
for many industrial processes e.g. inhibition of radical formation for preventing 
premature polymerization during processing, storage and transportation of unsaturated 
monomers. They exert their effects by scavenging or preventing the generation of ROS
 
(39)
 which can protect the formation of free radicals and retard the progress of many 
chronic diseases
 (40)
 including cancer, neurodegenerative, inflammation and 
cardiovascular diseases
 (41)
. 
 
1.7 CANCER: 
(42, 43)
 
The term carcinoma is the medical term for a malignant tumor derived from 
epithelial cells. It was Celsius who translated carcino into the Latin cancer, also 
meaning crab. Galen used "oncos" to describe all tumors, the root for the modern word 
oncology. 
Hippocrates described several kinds of cancers. He called benign tumors 
―oncos‖, Greek for swelling and malignant tumors ―carcinos‖, Greek for crab or 
crayfish. This name comes from the appearance of the cut surface of a solid malignant 
tumor; with a roundish hard centre surrounded by a pointy projection, vaugly 
resembling the shape of crab. He later added the suffix -oma, Greek for swelling, giving 
the name Carcinoma. 
 Since it was against Greek tradition to open the body, Hippocrates only 
described and made drawings of outwardly visible tumors on the skin, nose, and breasts. 
Treatment was based on the humor theory of four bodily fluids (black and yellow bile, 
blood, and phlegm). According to the patient's humor, treatment consisted of diet, 
blood-letting, and/or laxatives. Through the centuries it was discovered that cancer 
could occur anywhere in the body, but humor-theory based treatment remained popular 
until the 19th century with the discovery of cells. 
Cancer is the gross distortion of the cell behavior caused by numerous gene 
mutations and numerous abnormalities in the production of functioning proteins. The 
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specific abnormalities vary greatly, depending on the type of cancer as well as the type 
of tissue from which cancer has originated.  
Thus, there is not a single description of cancer or oncogenesis, because cancer 
is not a single disease. It is really a class of diseases all pertaining to unlimited cell 
growth that is potentially fatal to the organism.  
Cancer initiates from a single cell that has been transformed due to particular 
changes in its DNA. Some events such as exposure to radiation or exposure to chemical 
carcinogen, creates a change in genome. This may be a DNA mutation, or epigenetic 
modification. In comparison with normal cell, a neoplastic cell is hyper responsive to 
growth factors, under responsive to growth inhibitors, and has an increase in metabolic 
transport capabilities.  
A cancer cell tends to have an irregular shape, an abnormally appearing nucleus, 
is more mobile, is invasive, and generally shows a genomic instability. Thus the cancer 
cells look different, grow excessively and behave abnormally.  
Solid mass of cells is generally called as tumor or a neoplasm. But tumor is not 
always cancerous. A tumor may also be benign, benign tumors in humans can often 
identified and removed surgically. To be diagnosed as a cancer, a tumor must become 
malignant. It must gain capacity to invade surrounding tissues. 
Broadly, carcinomas are the cancers of epithelial cells; sarcomas are cancers of 
connective tissue or muscle cells, and leukemias are cancers of the blood or lymph 
systems.  In the normal human population, over 90% of all human cancers are 
carcinomas.
 
 
1.7.2 Causes of Cancer 
Cancer is a diverse class of diseases which differ widely in their causes and 
biology. The common thread in all known cancers is the acquisition of abnormalities 
in the genetic material of the cancer cell and its progeny. Research into the 
pathogenesis of cancer can be divided into three broad areas of focus. The first area 
of research focuses on the agents and events which cause or facilitate genetic 
changes in cells destined to become cancer. Second, it is important to uncover the 
precise nature of the genetic damage, and the genes which are affected by it. The 
third focus is on the consequences of those genetic changes on the biology of the 
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cell, both in generating the defining properties of a cancer cell, and in facilitating 
additional genetic events, leading to further progression of the cancer.  
 Chemical carcinogens:  Cancer pathogenesis is traceable back to DNA mutations 
that impact cell growth and metastasis. Substances that cause DNA mutations are 
known as mutagens, and mutagens that cause cancers are known as carcinogens. 
Particular substances have been linked to specific types of cancer. Tobacco 
smoking is associated with lung cancer and bladder cancer. Prolonged exposure to 
asbestos fibers is associated with mesothelioma. Many mutagens are also 
carcinogens, but some carcinogens are not mutagens. Alcohol is an example of a 
chemical carcinogen that is not a mutagen. Such chemicals are thought to promote 
cancers through their stimulating effect on the rate of cell mitosis.  
 Ionizing radiation: Sources of ionizing radiation, such as Radon gas, can cause 
cancer. Prolonged exposure to ultraviolet radiation from the sun can lead to 
melanoma and other skin malignancies.   
 Hormonal imbalances: Some hormones can act in a similar manner to non-
mutagenic carcinogens in that they may stimulate excessive cell growth. A well-
established example is the role of hyper estrogenic states in promoting endometrial 
cancer.  
 Immune system dysfunction: HIV is associated with a number of malignancies, 
including Kaposi's sarcoma, Non-Hodgkin's lymphoma, and HPV-associated 
malignancies such as anal cancer and cervical cancer. AIDS-defining illnesses 
have long included these diagnoses. The increased incidence of malignancies in 
HIV patients points to the breakdown of immune surveillance as a possible 
etiology of cancer. Certain other immune deficiency states (e.g. common variable 
immunodeficiency and IgA deficiency) are also associated with increased risk of 
malignancy.  
 Heredity: Most forms of cancer are "sporadic", and have no basis in heredity. 
There are, however, a number of recognised syndromes of cancer with a hereditary 
component, often a defective tumor suppressor allele.  
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 Other causes: A few types of cancer in non-humans have been found to be caused 
by the tumor cells themselves. This phenomenon is seen in Sticker's sarcoma, also 
known as canine transmissible venereal tumor. 
 
New Research in Cancer Treatment  
 Genetically engineered bacteria and viruses  
 Anti-cancer vaccines  
 Cancer markers  
 Cancer growth retarders / inhibitors 
1.8.1 Molecular modeling 
(44, 45) 
Molecular modeling is the investigation of molecular structure and properties using 
computational chemistry and graphical visualization techniques in order to provide 
possible 3D representation under a given set of circumstances. Most of the molecular 
modeling systems strive to provide some basic set of features, visualization and 
manipulation of 3D molecular models including rotatable bonds, structure building, 
molecular mechanics, and/or dynamics, conformational analysis, electronic properties, 
molecular surface displays and the calculation of various physical and/ or structural 
properties. Molecular modeling is composed of several interlinked activities:  
 Molecular Graphics: It allows the 3D visualization and manipulation of 
structure to allow visualization of different parts of molecule, to change the 
orientation of specific function while holding other constant and to look at other 
different feasible conformations. Stereochemistry relationship including 
detailed measurement of molecular geometry and conformations, calculations 
of electron densities, electrostatic potentials, energies and direct comparison of 
the key structural features of a range of biologically active structures can be 
done by molecular graphics. 
 Computational Chemistry: It is concerned with the simulation of atomic and 
molecular properties of compounds of medicinal interest through equations and 
with the numeric methods used to solve these equations on the computer.  
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 Statistical Modeling: It encompasses the search for quantitative relationship 
between the structure or properties of a series of compound and their resultant 
biological activities. 
 
1.8.2 Functions of Molecular Modeling 
1. Structure Generation: Molecular structure may be generated by a variety of    
procedures:   
 The crystal structure (if available) can be loaded from Cambridge 
crystallographic      data file. 
 2D structure can be converted to 3D by software programs such as Chem. 
Office 
 The structure can be built up by stitching together small fragments. 
 By modifying a known structure. 
2. Structure Visualization: One of the most popular uses of molecular modeling 
system is to visualize molecular structures in a desired form. Different methods are here 
to represent molecular structures: 
 Ball and Stick representation 
 Colored Stick representation 
 Space Fill representation  
 Stereo Line representation 
 
3. Conformation Generation: The biological activity of a drug molecule is 
supposed to depend on one single, unique conformation hidden among all the low energy 
conformations. Only the bioactive conformation can bind to the specific macromolecular 
environment at the active site of the receptor protein. It is widely accepted that bioactive 
conformation is not necessarily identical with the lowest energy-conformation. However, 
on the other hand it cannot be the conformation that is so high in energy that it is 
excluded from the population of conformations in solution. With the help of molecular 
modeling various conformations of a molecule can be explored. There are three methods 
for exploring of the conformations of a molecule: 
 Systematic or Grid search. 
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 Model building methods. 
 Random methods 
 
1.8.3 Molecular Interaction (Docking)
 (46)
  
  The interaction of a drug with its receptor is a complex process. Many factors are 
involved in the intermolecular association such as hydrophobic; Van der Waal‘s, 
hydrogen bonding and electrostatic forces.  
The process of ―DOCKING‖ a ligand to binding sites tries to mimic the natural 
course of interaction of the ligand and its receptor via a lowest energy pathway. Usually 
the receptor is kept rigid while the conformation of the drug molecule is allowed to 
change. The molecules are physically moved closer to one another and the preferred 
docked conformation is minimized. Molecular docking is a study of how two or more 
molecular structures, for example drug and enzyme or receptor of protein, fit together. 
The most important application of docking software is virtual screening. In virtual 
screening the most interesting and promising molecules are selected from an existing 
database for further research. This places demands on the used computational method; it 
must be fast and reliable. 
 
1.8.4 AutoDock 4.2 
AutoDock is a suite of automated docking tools. It is designed to predict how small 
molecules, such as substrates or drug candidates, bind to a receptor of known 3D 
structure. 
AutoDock 4 actually consists of two main programs: AutoDock performs the docking 
of the ligand to a set of grids describing the target protein; auto grid pre-calculates these 
grids. In addition to using them for docking, the atomic affinity grids can be visualized. 
This can help, for example, to guide organic synthetic chemists design better binders. 
 
AutoDock has applications in: 
 X-ray crystallography; 
 Structure-based drug design; 
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 Lead optimization; 
 Virtual screening (HTS); 
 Combinatorial library design; 
 Protein-protein docking; 
 Chemical mechanism studies. 
With AutoDock Tools or ADT set up, run and analyze AutoDock dockings and 
isocontour Auto Grid affinity maps, as well as compute molecular surfaces, display 
secondary structure ribbons, compute hydrogen-bonds, and do many more useful things. 
AutoDock Tools or ADT is used to  
 View molecules in 3D, rotate & scale in real time. 
 Add all hydrogen‘s or just non-polar hydrogen‘s. 
 Assign partial atomic charges to the ligand and the macromolecule (Gasteiger or 
Kollman United Atom charges). 
 Merge non-polar hydrogen‘s and their charges with their parent carbon atom. 
 Set up rotatable bonds in the ligand using a graphical version of Auto Tors. 
 Set up the Auto Grid Parameter File (GPF) using a visual representation of the 
grid box, and slider-based widgets. 
 Set up the AutoDock Parameter File (DPF) using forms. 
 Launch Auto Grid and AutoDock. 
 Read in the results of an AutoDock job and graphically display them. 
 View isocontoured Auto Grid affinity maps. 
1.8.5 Energy Calculation and Energy Minimization
 (47)
: 
It was hypothesized that a ligand or drug binds to the enzyme or receptor in its 
most stable form i.e. ‗minimum energy state‘ form and hence properties of this energy 
optimized molecule will give the information regarding physicochemical requirements 
which govern the biological activities. This forms the basis of energy calculation and 
energy minimization. Energy minimizing procedures can be divided in to two classes: 
 First derivative techniques (e.g. Steepest Descent, Conjugate Gradient, and              
Powell method).  
 Second derivative techniques (e.g. Newton-Raphson). 
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2.1 ANTI MICROBIAL ACTIVITY: 
 Zakir Hussain et al (2006)
 (48)
 synthesized and reported 4’-position containing 
electronegative groups in flavones (Fig 2.1) exhibited enhanced anti microbial than 
other synthesized compounds by agar well diffusion method. 
O
O
No2  
Fig: 2.1 
Suresh Babu et al (2006) 
(49)
 synthesized and reported Substituted 5-hydroxy-2-
phenyl-7-ethoxy-4H-chromen-4-one (Fig 2.2) shows more potent anti bacterial activity 
due to increase chain length by Serial dilution method. 
O
O
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OR
 
Fig 2.2 
Hakan Goker et al (2005)
 (50)
  Synthesized and reported amidino benzimidazoles 
substituted flavone (Fig2.3) exhibited enhanced anti microbial activity due to N-bulky 
alkyl substituent at the position C-6 by macro-broth dilution assay. 
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Fig: 2.3 
Brown et al (2008) 
(51)
 Synthesized and  reported 2-(4-bromophenyl)-7-methoxy-
4H-chromen-4-one (Fig 2.4) as a more potent anti fungal due to the electronegative 
halogen in the side chain by agar well diffusion method 
OMeO
O
Br  
Fig 2.4 
Gabriel Sagrera et al (2011)
 (52)
 Synthesized and reported substituted 
bioflavonoids (Fig 2.5) show potent activity against fungi in high concentration by Serial 
dilution method. 
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Fig 2.5 
LITERATURE REVIEW 
 
 
Department Of Pharmaceutical Chemistry  23 
Roberta Bernini et al (2008)
 (53)
 Synthesized and reported mentholated flavone 
(Fig 2.6) shows enhanced activity against fungi even at low concentration due to 
racemic modification by agar well diffusion method. 
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Fig: 2.6 
2.2 ANTI MALARIAL ACTIVITY:  
  G.Auffret et al (2007) 
(54)
 synthesized and reported piperazinyl flavone 
derivatives (Fig 2.7) shows potent anti malarial activity against Plasmodium falciparum 
by [
3
H] hypoxanthine incorporation method. 
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Fig 2.7 
Lee et al (2007)
 (55)
 Synthesized and  reported flavone derivative (Fig 2.8) shows 
enhanced anti malarial activity against Plasmodium falciparum even at low 
concentration by Giemsa stained slide method. 
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Fig 2.8 
R. Ortet et al (2010) 
(56)
 synthesized and reported methoxy flavone (artementin) 
(Fig 2.9) shows potent anti malarial activity at very low concentration by Giemsa stained 
slide method. 
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Fig 2.9 
Pranorm Khaomek et al (2008) 
(57)
 Isolated and reported prenylated flavonoids 
(Fig 2.10) from Erythrina fusca shows enhanced anti-malarial activity than standard 
chloroquine by Micro-test (Mark III) method. 
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Fig 2.10 
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2.3 ANTI OXIDANT:  
W.Chen et al (2006)
 (58) 
reported flavones with ortho hydroxy-amino group (Fig 
2.11) shows stronger antioxidant activity than the derivatives with mono hydroxy or 
ortho dihydroxy group 
O
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Fig 2.11 
S.H. Kim et al (2009) 
(59)
 Synthesized and reported glucose-containing flavones 
(Fig 2.12) showed potent DPPH and superoxide anion radical scavenging and lipid per 
oxidation inhibition activities. 
 
                                
 
 
 
 
                                                                  Fig 2.12 
A.Gomes et al (2009) 
(60)
 Synthesized and reported   2-tyrylchromones and 
flavones (Fig 2.13) showed significant anti oxidant property by ROS and RNS 
scavenging assays.  
 
 
 
                                                  
Fig 2.13 
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 J. Gong et al (2009) 
(61)
 Synthesized and reported 6-OH-5, 7-dimethoxy 
analogue (Fig 2.14) showed significant anti oxidant mechanism involved was proposed as 
inhibition of xanthine oxidase, which was superior to allopurinol. 
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Fig 2.14 
C. M. M. Santos et al (2010) 
(62)
 synthesized and reported the aryl flavones (Fig 
2.15) showed potent Superoxide radical scavenging, Hydrogen peroxide scavenging, 
Singlet oxygen scavenging, Peroxyl radical scavenging, Nitric oxide scavenging and 
Peroxynitrite scavenging  inhibition activities due to increase in number of hydroxyl 
group. 
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Fig 2.15 
 
2.4 ANTI –CANCER ACTIVITY: 
Kataoka et al (2004) 
(63) 
reported 2-(2’-amino-3’-methoxyphenyl)-4H-1-
benzothiopyran-4-one (Fig 2.16) shows a more potent inhibitory effect cell 
proliferation. 
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Fig 2.16 
Blank et al (2004)
 (64)
 Synthesized and reported 2’-nitroflavone, (Fig 2.17), 2’, 
6-dinitroflavone (Fig: 2.18)   Shows most potent anti proliferative activity.  
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                        Fig 2.17                                                                  Fig 2.18 
 
T.C. Wang et al (2005) 
(65)
 Synthesized and reported methyloxime-containing 
flavone and isoflavone derivatives (Fig 2.19) shows strong anti proliferative effect on 
HeLa cell line.  
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Fig 2.19 
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Poerwono et al (2010)
 (66)
 Synthesized and reported increase of the lipophilicity 
of the derivatives to interact with biological targets provided by the allyl or prenyl (Fig 
2.20) groups can be a basis to explain the improvement of antitumor activity.  
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Fig 2.20 
C. Pouget et al (2001) 
(67)
 reported methoxylated flavanones (Fig 2.21) were 
found to be potent inhibitors for their antiproliferative activity against MCF-7 human 
breast cancer cells. 
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Fig 2.21 
 
H. Liu et al (2004) 
(68) 
Synthesized and reported 6-chloro-2-(3, 5-
dimethoxyphenyl)-4H-chromen-4-one (Fig 2.22) shows a more potent inhibitory effect 
cell proliferation against HepG-2 cells. 
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Fig 2.22 
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2.5 Anti-Hepatotoxicity 
Viswanathan Pugalendi et al (2010) 
(69) 
reported 5, 7 dihydroxy flavone (Fig 
2.23) posses hepatoprotective activity which is evidenced by lowered serum hepatic 
marker enzyme activities. 
O
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OH  
Fig: 2.23 
 Sharstry et al (2010) 
(70)
 reported 3, 5, 7-trihydroxy-2-(3, 4-dihydroxyphenyl)-
4H-chromen-4-one (Fig 2.24) exhibited enhanced hepatoprotective activity against CCl4 
induced rats. 
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Fig: 2.24 
2.6 ANTI-ALZHIMERS ACTIVITY: 
R. Sheng et al. (2009) 
(71)
 reported the potent inhibitory action on Acetylcholine 
esterase of flavonoids (Fig 2.25) derivative which was superior to donepezil.  
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Fig 2.25 
M. Ono et al.(2009) 
(72) 
reported that Fluoropegylated (Fig 2.17) flavones with 
the dimethylamino group  shown anti - Alzheimer’s activity in brain of  Alzheimer’s 
disease model  mice, mechanism involved was proposed as prevention of  intensely 
stained β-amyloid plaques.  
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Fig 2.26 
 
2.7 ANTI HIV ACTIVITY: 
Veljkovic et al (2007) 
(73) 
reported flavones compounds (Fig 2.27)  shows  
antiretroviral for AIDS therapy due to their significant anti-HIV-1 activity and low 
toxicity. 
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Fig 2.27 
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2.8 ANTI COAGULANT ACTIVITY: 
 
Vasquez-Martinez et al (2007) 
(74)
 reported flavones derivative (Fig 2.28) shows 
potent inhibitors of human platelet mechanism involved by lipoxygenase inhibitors 
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Fig 2.28 
 
2.9 ANTI DIABETIC ACTIVITY: 
 
Hampson et al (2006) 
(75)
 synthesized and reported flavones (Fig 2.29) show anti 
diabetic activity mechanism involved was proposed as glycogen phosphorylase 
inhibitors. 
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Fig 2.29 
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2.10 CARDIO VASCULAR ACTIVITY: 
 
Zou et al (2010) 
(76)
 reported 5-acetyl-7-hydroxy-2-phenyl-4H-chromen-4-one 
(Fig 2.30) prevent the Vascular endothelial dysfunction disease.  
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Fig: 2.30 
2.11 ANTI-TUBERCULAR ACTVITY 
P. Puangsombat et al (2007)
 (77)
 reported   isolated 5-hydroxy-2-(2,4-
dihydroxyphenyl)-7-methoxy-6-((E)-3-methylbut-1-enyl)-3-(3-methylbut-2-enyl)-4H-
chromen-4-one (artocarpin) (Fig 2.31) shows potent anti-tubercular activity at low 
concentration by using microplate Alamar blue assay (MABA) method. 
O
O
 
Fig 2.31 
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3.1 OBJECTIVES 
In the past 60 years, antibiotics have been critical in the fight against infectious 
disease caused by bacteria and other microbes. However, disease-causing microbes that 
have become resistant to antibiotic drug therapy are an increasing public health problem. 
Another part of the problem is due to increasing use, and misuse, of existing antibiotics in 
human and veterinary medicine and in agriculture. 
Antimicrobial resistance is not a new problem but one that is becoming more 
dangerous; urgent and consolidated efforts are needed to avoid regressing to the pre-
antibiotic era. Drug resistance is becoming more severe and many infections are no 
longer easily cured, leading to prolonged and expensive treatment and greater risk of 
death. 
Microbial development of resistance, as well as economic incentives, has resulted 
in research and development in the search for new antibiotics in order to maintain a pool 
of effective drugs at all times. While the development of resistant strains is inevitable, the 
slack ways that we administer and use antibiotics has greatly exacerbated the process
 (78)
. 
Among the various factors that have contributed to the current resurgence of 
malaria, growing resistance to anti-malarial drugs is perhaps the most important. The 
rising all-cause mortality rate among African children is attributable directly to malaria 
and specifically to the rapidly increasing resistance to anti-malarial drugs. Drug 
resistance is also emerging as a serious problem in the Indian subcontinent. The number 
of effective drugs available to treat malaria is small and the rate at which resistance is 
growing is outpacing the development of new anti-malarials. Nearly all the anti-malarials 
that are in use today were developed almost 30 years ago and, in general, the 
pharmaceutical companies, particularly the multinationals, have little interest in 
developing new cure despite the enormous need.
 (79)
 
 
Flavones have attracted continuing interest because of their varied biological 
activities namely anti-bacterial, anti-fungal, anti-Malarial, anti-viral, anti-oxidant, 
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hepatoprotective, anti-inflammatory, anti-cancer, cardiovascular, anti-osteoporotic 
effects,
 
anti-allergic, Anti-Alzheimer and anti-thrombotic activity. 
 
Zakir Hussain et al (2006) synthesized and reported 4’-position containing 
electronegative groups in flavones (Fig 3.1) exhibited enhanced anti microbial activity 
than other synthesized compounds. 
Brown et al (2008) reported 2-(4-bromophenyl)-7-methoxy-4H-chromen-4-one 
(Fig 3.2)   as a more potent anti fungal due to the electronegative halogen in the side 
chain. 
Lee et al (2007) reported flavone derivative (Fig 3.3) shows enhanced anti 
malarial activity against Plasmodium falciparum even at low concentration (EC50 = 1.0 
μg/mL). 
R. Ortet et al (2010) reported methoxy flavone (artementin) (Fig 3.4) shows 
potent anti malarial activity at low concentration ((IC50= 3.37μg/ml). 
J. Gong et al (2009) reported 6-OH-5, 7-dimethoxy analogue (Fig 3.5) showed 
significant anti oxidant mechanism involved was proposed as inhibition of xanthine 
oxidase. 
A.Gomes et al (2009)
 
reported flavones (Fig 3.6) showed significant anti oxidant 
property by ROS and RNS scavenging assays. 
Kataoka et al (2004)
 
reported 2-(2’-amino-3’-methoxyphenyl)-4H-1-
benzothiopyran-4-one (Fig 3.7) shows a more potent inhibitory effect cell proliferation. 
Blank et al (2004)
 
reported 2’-nitroflavone, 2’, 6-dinitroflavone (Fig 3.8) shows 
most potent anti proliferative activity.  
 
The structural similarities of previously reported anti-microbial, anti-malarial, 
anti-oxidant, anti-cancer and our newly synthesised compounds (3.9) are shown below. 
Hence it is rational that to screen these compounds for cytotoxic, anti-malarial, anti 
microbial and antioxidant activities.   
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REPORTED COMPOUNDS: 
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PROPOSED COMPOUND: 
 
 
Fig 3.9 
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With this background the aim of our work is 
To synthesize, some newer novel flavones bearing various aryl carbonyl 
compounds, with the carefully selected auxophores like chloro, nitro, Hydroxy and 
methoxy aldehydes groups and to facilitate biological activities of lead molecule by the 
appropriate synthetic route for In-vitro Anti-Malarial, In-vitro anti-microbial, In-vitro 
Anti-cancer and In-vitro antioxidant activities. 
Molecular Docking studies 
Molecular docking study was on pf-DHFR-TS- Plasmodium falciparum 
dihydrofolate reductase-thymidylate synthase (PDB: 1J3I) protein on flavone moiety 
with substituted carbonyl compounds. 
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4. PLAN OF WORK:  
 Literature review and scheme development 
  Synthesis by conventional method. 
 Synthesis by microwave irradiation method  
 Physicochemical and Characterization studies 
 Evaluation of In-vitro antibacterial activity against 8 pathogenic bacteria and 4  
      Pathogenic fungal activity by Disc Diffusion Method and Minimum Inhibitory                 
      Concentration 
 Evaluations of In-Vitro anti malarial activity by candle jar method. 
 Evaluation In-vitro antioxidant study by DPPH, ABTS, FRAP assay method. 
 Evaluation In-vitro anti-cancer activity by MTT assay method. 
 Molecular docking studies 
PLAN OF WORK 
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5.0 GENERAL: 
DETERMINATION OF PHYSICOCHEMICAL PROPERTIES OF 
SYNTHESIZED COMPOUNDS 
 
MELTING POINT ANALYSIS  
Melting points of the synthesized compounds were determined in a one end fused 
capillary tube method by using Thermionic Model–C-LMP- 1 CAMPVEEL Serial. No. 
0712022 melting point apparatus, and were uncorrected. 
 
THIN LAYER CHROMATOGRAPHY ANALYSIS
 
Purity of the compounds was checked by TLC using silica gel G (0.5mm thickness) 
coated over glass plate (12 x 20 cm). For the determination Rf value the dried silica gel 
G coated over glass plate were used.  
Preparation of TLC plate: By using distilled water silica gel G slurry is prepared and 
poured on to a glass plate which is maintained on a level surface. The slurry is spread 
uniformly on the surface of the glass plate. After setting, the plates are dried in an oven 
at 50˚C or 15 minutes for activating the TLC plate 
Chromatogram was developed by ascending technique when solvent front travelled 
appropriate distance; plates were taken out and dried. The location of spot was detected 
by using iodine chamber.  
Rf = Distance travelled by solute / Distance travelled by solvent 
 
SOLUBILITY
 
Solubility the solubility of synthesised compound was tested in different solvents 
such as polar, semi polar, and non polar solvents. 
Polar solvent: A solvent in whose molecules there is either a permanent separation 
of positive and negative charges, or the centres of positive and negative charges do not 
coincide; these solvents have high dielectric constants, are chemically active, and form 
coordinate covalent bonds; examples are water and carboxylic acids etc.  
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Semi polar solvent: Semi-polar solvents may induce a certain degree of polarity in 
non-polar molecules and may thus act to improve the miscibility of polar and non-polar 
liquids; examples are alcohols and ketones etc. 
        nonpolar solvent: a liquid solvent without significant partial charges on any atoms, 
as in the hydrocarbons, or where the polar bonds are arranged in such a way that the 
effects of their partial charges cancel out, as in carbon tetrachloride. Liquid hydrocarbons 
are the most common examples. 
The following table 5.1 indicates the meanings of the terms used in statements of 
approximate solubilities. 
Table: 5.1 
Descriptive  term Approximate volume of solvent 
in milliliters per gram of solute 
Very soluble less than 1 
Freely soluble from 1-10 
Soluble from 10-30 
Sparingly soluble from 30-100 
Slightly soluble from 100-1000 
Very slightly soluble from 1000-10,000 
Insoluble or practically insoluble more than 10,000 
 
Clog P Value 
  Calculated Log P value is computer program which calculates the relative 
hydrophobicity of a molecule. The value of ClogP tells you how hydrophobic a 
molecule. The higher the ClogP value, the more hydrophobic the molecule is.  Clog P 
value is calculated using ChemDraw Ultra 8.0. 
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SPECTRAL STUDIES 
CONFIRMATION OF THE STRUCTURE OF SYNTHESIZED COMPOUNDS 
 
ULTRA VIOLET SPECTRAL ANALYSIS 
The maximum absorbance or λmax   of synthesized compounds were determined at 
0.01%w/v concentration in ethanol by using Shimadzu 2000, UV1700 ultraviolet 
Spectrophotometer at KMCH College of pharmacy. The maximum absorbance was 
measured in nm. 
 
INFRARED SPECTRAL ANALYSIS 
The IR Spectra of the synthesized compounds were recorded at KMCH college of 
pharmacy by JASCO-FT/IR -1700, Serial no B016861016 spectrophotometer in KBr 
disc. The IR value was measured in cm
-1
.  
 
NUCLEAR MAGNETIC RESONANCE SPECTRAL ANALYSIS 
The NMR Spectra of the synthesized compounds were recorded at IIT Madras by 
Bruker 300 MHz FT- NMR using TMS (Tetra Methyl Silane) as internal standard. The 
PMR (Proton Magnetic Resonance) spectroscopic values are measured in δ ppm in 
DMSO-d6. Compounds were particulars of work done on DSX-300/AV-III 400/DRX-
500/AV-III 500(S)/ (L) AV-700 NMR spectrometer. 
 
MASS SPECTRAL ANALYSIS 
The Mass Spectra of the synthesized compounds were recorded at IIT Madras in MS 
(EI) JEOL GC MATE 700 EV. 
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METHODOLOGY 
SERIES I: CONVENTIONAL METHOD 
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PROCEDURE 
5.1a Preparation of resacetophenone (FD 1) 
(80)
 
 Dissolve anhydrous zinc chloride (1.2M, 16.5g) in glacial acetic acid (15.8 ml) by 
heat at about 120
0
C on a sand bath. To this mixture add resorcinol (1M, 11 g) with 
constant stirring and continue heat upto 159
0
C.  Remove the heat source and the reaction 
mixture was kept on sand bath for 20 minutes. The resulting solution was diluted with a 
mixture of 25 ml of concentrated hydrochloric acid and 25 ml of water. The dark red 
solution was placed in an ice bath and cooled to 5
0
C. The resulting orange yellow 
precipitate was collected and recrystallized with ethanol. The percentage yield: 65%, mp: 
145
0
-150
0 
C. The compound was confirmed by IR spectra (3118 cm
-1
 –OH, 1689 cm-1 for 
keto group, 1592 cm
-1 
for aryl ring). 
5.1b Preparation of 4-acetylbenzene-1, 3-diyl bis (4-nitrobenzoate) (FD 2) 
(81)
 
 Resacetophenone (0.025 M, 3.8g), dry potassium carbonate (4g), acetone (6M, 12 
ml) and p-nitro benzoyl chloride (0.035M, 6.51g) were added slowly in a round bottom 
flask and reflux it for 6 hours. The Chocolate brown crude color product was collected, 
immediately used for next step. 
5.1c Preparation of 3-hydroxy-4-[3-(4-nitrophenyl)-3-oxopropanoyl] phenyl 4-nitro 
benzoate (FD 3)
 (81)
 
 The crude product 4-acetylbenzene-1, 3-diyl bis (4-nitrobenzoate) (FD 2) were 
mixed with 10% glacial acetic acid and stirred for 30 minutes.  The chocolate brown 
color product was obtained, rinsed with water, filtered, dried and recrystallized with 
ethanol. The percentage Yield: 58%, Mp: 160
0
-165
0 
C, Rf = 0.61 (Benzene: Pyridine: 
Ammonia [8:2:1 ratio]). The compound was confirmed by IR spectra (1768 cm
-1 
for 
esters, 1685 cm
-1 
for keto , 3116 for –OH group,1602 cm-1 for aryl ring, 1518 cm-1 N=O 
group) 
5.1d Preparation of 7-hydroxy-2-(4-nitrophenyl)-4H-chromen-4-one (FD 4)
 (81)
 
 Dissolve 3-hydroxy-4-[3-(4-nitrophenyl)-3-oxopropanoyl] phenyl 4-nitro 
benzoate (FD 3) (0.01 M, 4 gm) in 30 ml of acetone in a round bottom flask. Dissolve 
sodium acetate (0.004 M, 0.3gm) in glacial acetic acid (10 ml) in a beaker. Mix both the 
solution and reflux it for 3 hours. Pour the resulting mixture in crushed ice (150 gm) and 
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stir well. Filter the dark straw color product, dried and recrystallized with ethanol. The 
percentage yield: 60%, Mp: 190
0-
195
0
C. Rf = 0.58 (Benzene: Pyridine: Ammonia [8:2:1 
ratio]). The compound was confirmed by IR spectra (peaks absent
 
for esters, 1689 cm
-1 
for keto, 1248 cm
-1
 for Ar-O-R , 3111 for –OH group 1607 cm-1 for aryl ring, 1524 cm-1 
N=O group). 
5.1e Preparation of 7-hydroxy-2-(4-aminophenyl)-4H-chromen-4-one (FD 5) 
(82)
 
 Dissolve 7-hydroxy-2-(4-nitrophenyl)-4H-chromen-4-one (FD 4) (0.01M, 2.82g) 
in conc. HCl (13 ml), ethanol (100 ml), and SnCl2 (2.00 g, 10.0 mmol) were added 
slowly. The suspension was heat at 80 
0
C for 1 hour, cool to room temperature.  The solid 
was filtered, washed with concentrated HCl, water and dilute ammonium, and dried in 
vacuum to give dark brown color product of  7-hydroxy-2-(4-aminophenyl)-4H-chromen-
4-one (FD 5). The percentage yield: 60%, Mp: 225
0
-230
0
C, Rf = 0.56 (Benzene: 
Pyridine: Ammonia [8:2:1 ratio]). 
5.1f Preparation of 7-hydroxy-2-(4-Substituted amino phenyl)-4H-chromen-4-one 
(DPN 1-15)
 (83)
 
To a suspension equal mole of aryl aldehydes / Ketones and 7-hydroxy-2-(4-
aminophenyl)-4H-chromen-4-one (FD 5) (0.005 mol) in ethanol (10 ml). The 
suspension was heated until a clear solution was obtained. A few drops of conc. sulfuric 
acid were added as a catalyst and the solution was refluxed for 3 h on a water bath. The 
precipitated solid was filtered off and recrystallized from ethanol. Physiochemical 
parameters and analytical data were given in the table 5.1 & 5.5. 
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SERIES II: MICROWAVE IRRADIATION METHOD 
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PROCEDURE 
5.2a Preparation of (E)-1-(2, 4-dihydroxyphenyl)-3-(4-nitrophenyl) prop-2-en-1-one 
(MD 1): 
(84)
 
A solution of sodium hydroxide (2.5 mmole in 10ml water) in ethanol (10 ml) 
was added to mixture of P-Nitro Benzaldehyde and resacetophenone (1mmole each) in a 
conical flask. Heat on water bath for about 20 minutes, the reaction mixture was 
quenched into the ice and then conc. HCl was added slowly with stirring till the reaction 
mixture became acidic. A wine red solid was separated, filtered and washed with ice 
water followed by recrystallization using absolute alcohol to afford 7-hydroxy-2-(4-
nitrophenyl)-4H-chromen-4-one. The percentage Yield: 78%, Mp: 236
0
-238
0 
C, Rf = 0.67 
(Benzene: Pyridine: Ammonia [8:2:1 ratio]). 
5.2b Preparation of 7-hydroxy-2-(4-nitrophenyl)-4H-chromen-4-one (MD 2):
 (84)
 
7-hydroxy-2-(4-nitrophenyl)-4H-chromen-4-one (1mmole) was suspended in 
DMSO (2ml) and to this solution iodine (0.02 mmole) was added. The mixture was 
subjected to microwave irradiation for 2 minutes at 450 W. Then it is diluted with water 
and extracted with diethyl ether. The organic layer was washed with 20% aqueous 
sodium thiosulphate, water and dried over anhydrous sodium sulphate. Then it is 
concentrated to get the orange yellow product 7-hydroxy-2-(4-nitrophenyl)-4H-chromen-
4-one. The percentage Yield: 71%, Mp: 160
0
-165
0 
C, Rf = 0.58 (Benzene: Pyridine: 
Ammonia [8:2:1 ratio]). 
5.2c Preparation of 7-hydroxy-2-(4-aminophenyl)-4H-chromen-4-one (MD 3)
 (82)
 
Dissolve 7-hydroxy-2-(4-nitrophenyl)-4H-chromen-4-one (MD 2) (0.01M, 2.82g) 
in conc. HCl (13 ml), ethanol (100 ml), and SnCl2 (2.00 g, 10.0 mmol) were added 
slowly. The suspension was heat at 80 
0
C for 1 hour, cool to room temperature.  The solid 
was filtered, washed with concentrated HCl, water and dilute ammonium, and dried in 
vacuum to give dark brown color product of  7-hydroxy-2-(4-aminophenyl)-4H-chromen-
4-one (MD 3). The percentage yield: 98%, Mp: 227
0
-231
0
C Rf = 0.61 (Benzene: 
Pyridine: Ammonia [8:2:1 ratio]). 
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5.2d Preparation of 7-hydroxy-2-(4-Substituted amino phenyl)-4H-chromen-4-one 
(Compound MWP 1-8) 
(85)
 
Equal mole of 7-hydroxy-2-(4-aminophenyl)-4H-chromen-4-one (MD 3) and aromatic 
aldehydes and ketones   were mixed together at ambient temperature in a conical flask. 
The mixture was subjected to microwave irradiation for an optimized time. The crude 
products were recrystallized with ethanol. The Physiochemical parameters and analytical 
data were given in the table 5.2 and 5.5. 
 
5.3 DOCKING ANALYSIS 
Compounds DPN 1-15 were used for docking on Dihydrofolate reductase and 
SGPT (PDB ID: 1VDR) Docking studies of designed compounds were carried out 
using AutoDock module version 4.1. The software package running on multi-processor 
Linux PC. AUTODOCK has previously been validated & applied successfully to 
predict the binding orientation of many ligands. 
METHODOLOGY 
The steps involved in docking are as follows: 
 Ligand structure: The chemical structure of each ligand was drawn using build 
module. 
 Ligand preparation:  In order to prepare high quality, all-atom 3D structures for 
large numbers of drug-like molecules, starting with the 3D structures in SD Maestro 
format, LigPrep was used. LigPrep produced a single, low-energy, 3D structure with 
corrected chiralities for each successfully processed input structure. 
 Preparation of protein: The typical structure ﬁle from the PDB is not suitable for 
immediate use in molecular modeling calculations. A typical PDB structure ﬁle 
consists only of heavy atoms and may include a co-crystallized ligand, water 
molecules, metal ions, and cofactors. Some structures are multimeric, and may need 
to be reduced to a single unit. Because of the limited resolution of X-ray experiments, 
it can be difficult to distinguish between NH and O, and the placement of these 
groups must be checked. PDB structures may be missing information on connectivity, 
which must be assigned, along with bond orders and formal charges. This was done 
using the Protein Preparation Wizard. 
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 Receptor Grid Generation: Receptor grid generation requires a “prepared” structure: 
an all atom structure with appropriate bond orders and formal charges. AutoDock 
searches for favourable interactions between one or more ligand molecules and a 
receptor molecule, usually a protein. The shape and properties of the receptor are 
represented on a grid by several different sets of fields that provide progressively 
more accurate scoring of the ligand poses. The options in each tab of the Receptor 
Grid Generation panel allow defining the receptor structure by excluding any co-
crystallized ligand that may be present, determine the position and size of the active 
site as it will be represented by receptor grids, and set up AutoDock constraints. A 
grid area was generated around the binding site of the receptor. 
 Ligand Docking: This is carried out using AUTODOCK. AutoDock searches for 
favourable interactions between one or more ligand molecules and a receptor 
molecule, usually a protein. Each ligand acts as single molecule, while the receptor 
may include more than one molecule, e.g., a protein and a cofactor. AutoDock was 
run in rigid or flexible docking modes; the latter automatically generated 
conformations for each input ligand. The combination of position and orientation of a 
ligand relative to the receptor, along with its conformation in flexible docking, is 
referred to as a ligand pose. The ligand poses that AutoDock generates pass through a 
series of hierarchical filters that evaluate the ligand’s interaction with the receptor. 
The initial ﬁlters test the spatial ﬁt of the ligand to the deﬁned active site, and examine 
the complementarily of ligand-receptor interactions using a grid-based method 
patterned after the empirical ChemScore function. Poses that passed these initial 
screens entered the ﬁnal stage of the algorithm, which involves evaluation and 
minimization of a grid approximation to the OPLS-AA non bonded ligand-receptor 
interaction energy. Final scoring is then carried out on the energy-minimized poses. 
Docking Procedure 
Docking studies of compounds selected compounds were performed using 
proteins pf-DHFR-TS- Plasmodium falciparum dihydrofolate reductase-thymidylate 
synthase (PDB ID: 1J3I) obtained from the RCSB Protein Data Bank, 
http://www.rcsb.org/pdb 
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Experiments were performed using the program AUTODOCK. Coordinates of 
the full-length substrate-complexed dimmer were prepared for AutoDock 4.0 
calculations by running the protein preparation wizard. The p-prep script produces a 
new receptor file in which all residues are neutralized except those that are relatively 
close to the ligand (if the protein is complexed with a ligand) or form salt bridges. The 
impref script runs a series of restrained impact energy minimizations using the Impact 
utility. Minimizations were run until the average root mean square deviation (rmsd) of 
the non-hydrogen atoms reached 0.3Å. 
AutoDock uses two boxes that share a common centre to organize its 
calculations: a larger enclosing box and a smaller binding box. The grids themselves are 
calculated within the space defined by the enclosing box. The binding box defines the 
space through which the centre of the defined ligand will be allowed to move during 
docking calculations. It provides a measure of the effective size of the search space. 
The only requirement on the enclosing box is that it be large enough to contain all 
ligand atoms, even when the ligand centre is placed at an edge or vertex of the binding 
box. Grid files were generated using the co crystallized ligand at the centre of the two 
boxes.  
The size of the binding box was set at 20 Å in order to explore a large region of 
the protein. The three-dimensional structures of the compounds were constructed using 
the Maestro interface. The initial geometry of the structures was optimized using the 
OPLS-2005 force field performing 1000 steps of conjugate gradient minimization. The 
compounds were subjected to flexible docking using the pre-computed grid files. For 
each compound the 100 top-scored poses were saved and analyzed. The results were 
tabulated in table 5.6. 
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Table 5.1: PHYSIOCHEMICAL DATA OF COMPOUNDS DPN 1-15 
 
Comp. 
code 
Structure 
(Ar/R) 
 
Color 
Molecular 
formula 
Molecular 
Wt 
MP  (
0
C) %Yield 
*Rf 
value 
 
Clog P 
value 
DPN-01 Benzaldehyde 
Dark yellow C22H15NO3 341.36 160-165 85% 0.69 3.93 
DPN-02 
2-Hydroxy 
Benzaldehyde 
Brown C22H15NO4 357.56 176-180 65% 0.84 4.17 
DPN-03 
4-Hydroxy 
Benzaldehyde 
Dark Brown C22H15NO4 357.56 194-198 62% 0.84 4.17 
DPN-04 
2-Chloro 
Benzaldehyde 
Light  Brown C22H14ClNO3 375.07 145-150 69% 0.85 4.64 
DPN-05 
3-Chloro 
Benzaldehyde 
Light brown C22H14ClNO3 375.07 165-170 62% 0.85 4.64 
DPN-6 
4-Chloro 
Benzaldehyde 
Brown C22H14ClNO3 375.07 135-140 71% 0.86 4.64 
DPN-07 
2-Nitro 
Benzaldehyde 
Dark brown C24H14N2O5 386.86 109-112 67% 0.82 3.67 
DPN-08 
4-Nitro 
Benzaldehyde 
Brown C24H14N2O5 386.86 118-122 60% 0.83 3.67 
DPN-09 
3-Fluro 
Benzaldehyde 
Brown C22H14FNO3 359.35 167-170 78% 0.62 
4.07 
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*Solvent system- Benzene: Pyridine: Ammonia (8:2: 1 ratio) Detection- UV Chamber 
Solubility- DMSO and benzene 
 
 
 
 
 
 
 
 
 
 
 
DPN-10 Anisaldehyde 
Pale Red C23H17NO4 371.39 138-142 74% 0.87 4.28 
DPN-11 
4-Dimethyl 
amino 
Benzaldehyde 
Dark Red 
C24H20N2O3 384.43 105-110 81% 0.56 
4.62 
DPN-12 Vanillin 
Grayish C23H17NO5 387.11 120-125 62% 0.77 4.03 
DPN-13 
Cinnamaldehy
de 
Dark Brown C24H17NO3 367.12 85-90 65% 0.58 4.27 
DPN-14 Acetophenone 
Dark green 
C23H17NO3 355.12 90-95 52% 0.62 5.15 
DPN-15 Benzophenone 
Dark Brown C28H19NO3 417.14 80-85 55% 0.74 6.17 
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Table 5.2: PHYSIOCHEMICAL DATA OF COMPOUNDS MWP 1-8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Comp. code 
Structure 
(Ar/R) 
Molecular 
formula 
Color 
Molecula
r Wt 
MP  (
0
C) 
%Yiel
d 
*Rf 
value 
Clog P 
value 
Time 
(sec)  
MWP-01 Benzaldehyde 
C22H15NO3 
Dark 
yellow 
341.36 
163-167 94% 0.70 3.93 
150 
MWP -02 
4-Hydroxy 
Benzaldehyde 
C22H15NO4 Dark 
Brown 
357.56 193-196 95% 0.83 4.17 180 
MWP -03 
4-Chloro 
Benzaldehyde 
C22H14ClNO3 Brown 375.07 136-140 98% 0.87 4.64 180 
MWP -04 
4-Nitro 
Benzaldehyde 
C24H14N2O5 Brown 386.86 119-121 96% 0.84 3.67 180 
MWP -05 Anisaldehyde 
C23H17NO4 Pale Red 371.39 138-143 97% 0.86 4.28 150 
MWP -06 
4-Dimethyl 
amino 
Benzaldehyde 
C24H20N2O3 Dark Red 384.43 108-110 94% 0.55 4.62 
210 
MWP -07 Vanillin 
C23H17NO5 Grayish 387.11 121-125 97% 0.79 4.03 180 
MWP -08 Acetophenone C23H17NO3 
Dark 
green 
355.12 91-94 98% 0.64 5.15 210 
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Table 5.3: COMPARISON BETWEEN CONVENTIONAL METHOD AND MICROWAVE IRRADIATION METHOD IN 
PERCENTAGE YIELD 
 
S.NO 
 
Substituent Compound 
Percentage yield 
Conventional method Microwave irradiation 
method 
1 Benzaldehyde 85% 94% 
2 4-Hydroxy Benzaldehyde 62% 95% 
3 4-Chloro Benzaldehyde 71% 98% 
4 4-Nitro Benzaldehyde 60% 96% 
5 Anisaldehyde 74% 97% 
6 
4-Dimethyl amino Benzaldehyde 81% 94% 
7 Vanillin 62% 97% 
8 Acetophenone 52% 98% 
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Table 5.4: SPECTRAL DATAS OF SYNTHESISED COMPOUND DPN 1-15 
 
Comp. 
code 
Molecular Structure 
λmax 
(nm) 
 
(IR) υmax(KBr/cm
-
1
) 
1HNMR (δ- ppm) MASS SPECTROSCOPIC 
DATA 
Mol. 
wt 
Base 
peak 
(m/z) 
Molecula
r ion 
peak  
(m/z) 
FD 5 
O
O
HO
NH2
 
2-(4-aminophenyl)-7-hydroxy-4H-chromen-4-one 
329 
1402 (C=C aryl)  
714 (C-C aromatic 
region)                           
1693 (C=O)                                                   
1108 (C-O-C)                                            
3116 (-OH) 
1540 (-NH2 
Primary) 
13.63 (s,1H, -OH), 
3.3(S,2H, -NH2) 
12.18 (S,1H,
C
O
C
H
) 
8.19-8.14 (m, 4H, C 
2,3,5,6 -H of Aryl), 8.30-
8.40 (m, 3H, C1’,3’,4’ 
aryl ring) 
253.05 77.44 253.25 
DPN-01 
O
O
OH
N CH
 
2-[4-(benzylideneamino)phenyl]-7-hydroxy-4H-
chromen-4-one 
 
446 
 
1605 (C=C aryl)  
716 (C-C aromatic 
region)                                                      
1691 (C=O)                                                   
1106 (C-O-C)                                            
3119 (-OH) 
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DPN-02 
O
O
HO
N C
H
HO
 
7-hydroxy-2-{4-[(2-hydroxybenzylidene) 
amino]phenyl}-4H-chromen-4-one 
 
420 
1604 (C=C aryl) 
715(C-C aryl) 
838 (p-substituent)       
1692 (C=O)                                                   
1107 (C-O-C)                                            
3115 (-OH 
aromatic) 
1349(-OH 1
0
 
alcohol) 
 
 
    
DPN-03 
 
O
O
HO
N C
H
OH
 
7-hydroxy-2-{4-[(4-hydroxybenzylidene) 
amino]phenyl}-4H-chromen-4-one 
 
420 
1602 (C=C aryl) 
 717 (C-C aryl) 
838 (p-substituent)       
1689 (C=O)                                                   
1104 (C-O-C)                                            
3119 (-OH 
aromatic) 
1349(-OH 1
0
 
alcohol) 
 
 
13.62 (s,1H, -OH),  
12.18 (S,1H,
C
O
C
H
), 
 8.14-8.18 (m, 7H, C 
2,3,5,6 , C1’,3’,4’ -H of 
Aryl ring ),  
8.29-8.41 (m, 4H, C 
A,C,E,F –H Aryl ring) 
2.65-3.59(s,1H,-N=CH-) 
   
DPN-04 
O
O
HO
N C
H
Cl
 
2-(4-(2-chlorobenzylideneamino)phenyl)-7-
hydroxy-4H-chromen-4-one 
465 
1602 (C=C aryl)  
714 (C-C aromatic 
region)                                                      
1693 (C=O)                                                   
1106 (C-O-C)                                            
3114 (-OH) 
798 (o-C-Cl) 
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DPN-05 
O
O
HO
N C
H
Cl
2-(4-(3-chlorobenzylideneamino)phenyl)-7-
hydroxy-4H-chromen-4-one 
465 
1604 (C=C aryl)  
716 (C-C aromatic 
region)                                                      
1698 (C=O)                                                   
1223 (C-O-C)                                            
3114 (-OH) 
800 (C-Cl) 
 
    
DPN-06 
O
O
HO
N C
H
Cl
 
2-(4-(4-chlorobenzylideneamino)phenyl)-7-
hydroxy-4H-chromen-4-one 
465 
1602 (C=C aryl)  
717 (C-C aromatic 
region)                                                      
1698 (C=O)                                                   
1223 (C-O-C)                                            
3114 (-OH) 
820 (C-Cl) 
 
13.1 (s,1H, -OH),  
12.58 (S,1H,
C
O
C
H
), 
 7.48-7.72 (m, 4H, C 
2,3,5,6 -H of Aryl),  
7.79-7.94 (m, 3H, 
C1’,3’,4’ -H aryl ring) 
8.14-8.34 (m, 3H, C 
A,B,C –H Aryl ring) 
3.40-3.59 (s, 1H, -
N=CH-) 
375.07 250.90 375.77 
DPN-07 
O
O
HO
N C
H
O2N
 
2-(4-(2-nitrobenzylideneamino)phenyl)-7-hydroxy-
4H-chromen-4-one 
444 
1603 (C=C aryl)  
716 (C-C aromatic 
region)                                                      
1698 (C=O)                                                   
1105 (C-O-C)                                            
3113 (-OH) 
1530 (N=O) 
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DPN-08 
O
O
HO
N C
H
NO2
 
2-(4-(4-nitrobenzylideneamino)phenyl)-7-hydroxy-
4H-chromen-4-one 
444 
1603 (C=C aryl)  
717 (C-C aromatic 
region)                                                      
1698 (C=O)                                                   
1225 (C-O-C)                                            
3114 (-OH) 
1528 (N=O) 
 
13.62 (s,1H, -OH),  
12.18 (S,1H,
C
O
C
H
), 
 6.95-6.99 (m, 4H, C 
2,3,5,6 -H of Aryl),  
8.00-8.19 (m, 3H, 
C1’,3’,4’ -H aryl ring) 
8.29-8.41 (m, 4H, C 
A,B,D,E –H Aryl ring) 
3.40-3.59 (s, 1H, -
N=CH-) 
386.86 149.46 386.32 
DPN-09 
O
O
HO
N C
H
F
 
2-(4-(3-fluorobenzylideneamino)phenyl)-7-hydroxy-
4H-chromen-4-one 
498 
1604 (C=C aryl)  
717 (C-C aromatic 
region)                                                      
1691 (C=O)                                                   
1107 (C-O-C)                                            
3115 (-OH) 
876 (C-F) 
 
    
DPN-10 
O
O
HO
N C
H
OCH3
 
2-(4-(4-methoxybenzylideneamino)phenyl)-7-
hydroxy-4H-chromen-4-one 
468 
1599 (C=C aryl)  
717 (C-C aromatic 
region)                                                      
1692 (C=O)                                                   
1023 (C-O-C)                                            
3116 (-OH) 
605 (C=C alkyl) 
834 (p-substituted) 
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DPN-11 
O
O
HO
N C
H
N
CH3
CH3
 
2-(4-{[4-
(dimethylamino)benzylidene]amino}phenyl)-7-
hydroxy-4H-chromen-4-one 
 
342 
1590 (C=C aryl)  
1400(C=C 
stretching) 
719 (C-C aromatic 
region)                                                      
1712 (C=O)                                                   
1268 (C-O-C)                                            
3125 (-OH) 
834 (p-substituted) 
1168(3
0
amine) 
 
 384.43 152.61 384.43 
DPN-12 
O
O
HO
N C
H
OH
OCH3
 
7-hydroxy-2-{4-[(4-hydroxy-3-
methoxybenzylidene) amino]phenyl}-4H-chromen-
4-one 
 
380 
1596 (C=C aryl)  
716 (C-C aromatic 
region)                                                      
1666 (C=O)                                                   
1269 (C-O-C)                                            
3118 (-OH Phenol) 
1154 (-OH 1
0
) 
821(di substituted) 
    
DPN-13 
 
O
O
N CH
HO
 
2-((4Z)-4-((E)-3-phenylallylideneamino)phenyl)-7-
hydroxy-4H-chromen-4-one 
476 
1603 (C=C aryl)  
719 (C-C aromatic 
region)                                                      
1694 (C=O)                                                   
1106 (C-O-C)                                            
3119 (-OH) 
1620 (C=C 
alkenes) 
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DPN-14 
O
O
N C
CH3
HO
 
2-((Z)-4-(1-phenylethylideneamino)phenyl)-7-
hydroxy-4H-chromen-4-one 
628 
1605 (C=C aryl)  
716 (C-C aromatic 
region)           
1401 (Ar-C )                                            
1693 (C=O)                                                   
1107 (C-O-C)                                            
3117 (-OH) 
1350 (Methyne C-
H bend) 
 
    
DPN-15 
O
O
N C
HO
 
2-(4-(biphenyl methylene amino)phenyl)-7-
hydroxy-4H-chromen-4-one 
539 
1600 (C=C aryl)  
719 (C-C aromatic 
region) 
1401 (Ar-C )                                                                                                  
1691 (C=O)                                                   
1109 (C-O-C)                                            
3119 (-OH) 
1350 (Methyne C-
H bend) 
 
 
 
 
    
EXPERIMENTAL 
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SPECTRAL DATAS OF SYNTHESISED COMPOUND MWP 1-8 
 
Comp. 
code 
Molecular Structure 
λmax 
(nm) 
 
(IR) υmax(KBr/cm
-1
) 
MD 03 
O
O
HO
NH2
 
2-(4-aminophenyl)-7-hydroxy-4H-chromen-4-one 
329 
1402 (C=C aryl)  
714 (C-C aromatic region)                           
1693 (C=O)                                                   
1108 (C-O-C)                                            
3116 (-OH) 
1540 (-NH2 Primary) 
MWP -01 
O
O
OH
N CH
 
2-[4-(benzylideneamino)phenyl]-7-hydroxy-4H-
chromen-4-one 
 
446 
 
1608 (C=C aryl)  
719 (C-C aromatic region)                                                      
1695 (C=O)                                                   
1104 (C-O-C)                                            
3121 (-OH) 
 
 
MWP -02 
 
O
O
HO
N C
H
OH
 
420 
1605 (C=C aryl) 
 716 (C-C aryl) 
836 (p-substituent)       
1692 (C=O)                                                   
1106 (C-O-C)                                            
3116 (-OH aromatic) 
1351(-OH 1
0
 alcohol) 
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7-hydroxy-2-{4-[(4-hydroxybenzylidene) 
amino]phenyl}-4H-chromen-4-one 
 
 
MWP -03 
O
O
HO
N C
H
Cl
 
2-(4-(4-chlorobenzylideneamino)phenyl)-7-
hydroxy-4H-chromen-4-one 
465 
1603 (C=C aryl)  
718 (C-C aromatic region)                                                      
1694 (C=O)                                                   
1224 (C-O-C)                                            
3119 (-OH) 
822(C-Cl) 
 
MWP -04 
O
O
HO
N C
H
NO2
 
2-(4-(4-nitrobenzylideneamino)phenyl)-7-hydroxy-
4H-chromen-4-one 
444 
1607 (C=C aryl)  
719 (C-C aromatic region)                                                      
1694 (C=O)                                                   
1222 (C-O-C)                                            
3115 (-OH) 
1532 (N=O) 
 
MWP -05 
O
O
HO
N C
H
OCH3
2-
(4-(4-methoxybenzylideneamino)phenyl)-7-
hydroxy-4H-chromen-4-one 
468 
1602 (C=C aryl)  
714 (C-C aromatic region)                                                      
1698 (C=O)                                                   
1020 (C-O-C)                                            
3117 (-OH) 
606 (C=C alkyl) 
832 (p-substituted) 
 
EXPERIMENTAL 
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MWP -06 
O
O
HO
N C
H
N
CH3
CH3
 
2-(4-{[4-
(dimethylamino)benzylidene]amino}phenyl)-7-
hydroxy-4H-chromen-4-one 
 
342 
1593 (C=C aryl)  
1404(C=C stretching) 
715 (C-C aromatic region)                                                      
1706 (C=O)                                                   
1258 (C-O-C)                                            
3120 (-OH) 
832 (p-substituted) 
1162 (3
0
amine) 
 
MWP -07 
O
O
HO
N C
H
OH
OCH3
 
7-hydroxy-2-{4-[(4-hydroxy-3-
methoxybenzylidene) amino]phenyl}-4H-chromen-
4-one 
 
380 
1598 (C=C aryl)  
718(C-C aromatic region)                                                      
1669 (C=O)                                                   
1272 (C-O-C)                                            
3112 (-OH Phenol) 
1148 (-OH 1
0
) 
822(di substituted) 
MWP -08 
O
O
N C
CH3
HO
 
2-((Z)-4-(1-phenylethylideneamino)phenyl)-7-
hydroxy-4H-chromen-4-one 
628 
1602 (C=C aryl)  
720 (C-C aromatic region)           
1399 (Ar-C )                                            
1699 (C=O)                                                   
1103 (C-O-C)                                            
3116 (-OH) 
 
EXPERIMENTAL 
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Table 5.6: DOCKING SCORE  
S.No Compound code Docking score 
Amino acid 
 (Active binding site) 
1 DPN-03 - - 
2 DPN-06 -6.07 ARG 350 
3 DPN-08 -9.81 LEU 498 
4 DPN-10 -7.3 SER 340 
5 DPN-11 -6.9 GLY 186 
6 DPN-12 -6.37 TY 440 
7 DPN-13 - - 
8 DPN-14 -3.5 GLY 144 
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DOCKING INTERACTION:  
 
 
EXPERIMENTAL 
 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY  66 
  
EXPERIMENTAL 
 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY  67 
 
Graphical representation of Docking interaction 
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SPECTRAL DATAS OF SYNTHESISED COMPOUND BY CONVENTIONAL 
METHOD 
IR SPECTRA: 
 
FD 3 
FD 4 
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FD 5 
 
DPN 01 
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DPN 02 
 
DPN 03 
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DPN 04 
 
DPN 05 
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DPN 06 
 
DPN 07 
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DPN 08 
 
DPN 09 
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DPN 10 
 
DPN 11 
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DPN 12 
 
DPN 13 
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DPN 14 
 
DPN 15 
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NMR SPECTRA 
COMPOUND FD 05 
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COMPOUND DPN 03 
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COMPOUND DPN 06 
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COMPOUND DPN 08 
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MASS SPECTRA: 
 
FD 05 
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DPN 06 
EXPERIMENTAL  
 
 
Department of Pharmaceutical Chemistry 91 
 
 
DPN 08 
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DPN 11 
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SPECTRAL DATAS OF SYNTHESISED COMPOUNDS BY MICROWAVE 
IRRADIATION METHOD: 
IR SPECTRA: 
 
FM 01 
 
FM 02 
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FM 03 
 
MWD 01 
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MWD 02 
 
MWD 03 
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MWD 04 
 
MWD 05 
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MWD 06 
MWD 07 
EXPERIMENTAL  
 
 
Department of Pharmaceutical Chemistry 98 
 
 
MWD 08 
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6.1 In-vitro Anti Microbial screening by Zone of inhibition and MIC method  
6.2 In-Vitro Anti Malarial screening by Candle jar method  
6.3 In-vitro Antioxidant screening by DPPH, FRAP, ABTS assays method.  
6.4 In-vitro Anti-cancer screening by MTT assay. 
 
6.1 IN-VITRO ANTIMICROBIAL STUDIES
 (86)
 
The in vitro antibacterial activity of the series of synthesized compounds was 
evaluated against 8 pathogenic bacteria and 4 pathogenic fungi. The bacteria and fungus 
strains were procured from the bacterial repository of Department of Biotechnology, 
KMCH College of Pharmacy Coimbatore. 
 Dimethyl sulphoxide was used to prepare stock solution for synthesized drugs. 
Subsequent dilutions of the stock were also made with above solvent. Muller Hinton 
agar media (Hi-media) for bacteria and Sabouraud’s Dextrose Broth for fungus were 
used to subculture various strain of bacteria and fungus as well for determining the 
MIC’s of synthesized compounds by serial dilution method. 
Initially the sensitivity of various microorganisms to the synthesized compounds 
was determined by disc diffusion method.  
 
Compounds used for activity: DPN 1-15 (100μg/disc) 
Standard drugs used for activity:  
Ciprofloxacin (antibacterial) (5μg/disc) 
   Clotrimazole (antifungal) (5μg/disc) 
     
4.1.1 DISC DIFFUSION METHOD 
The disc diffusion method, the drug potency is based on measurement of the 
diameter of zone of inhibition surrounding cylinder disc which are placed on the 
surface of a nutrient medium previously inoculated with a culture of suitable 
BIOLOGICAL SCREENING 
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microorganisms. Inhibition produced by the test compound is compared with that 
produced by known concentration of reference standard.  
List of bacterial and fungal strains used  
Bacteria 
1. Micrococcus luteus NCIM 2169 (Gram positive) 
2. Bacillus subtilis NCIM 2063 (Gram positive) 
3. Staphylococcus aureus NCIM 2079 (Gram positive) 
4. Corynebacterium NCIM 2268 (Gram positive) 
5. Vibrio cholera MTCC 1738 (Gram negative) 
6. Escherichia coli NCIM 2068 (Gram negative) 
7. Pseudomonas aeruginosa NCIM 2206 (Gram negative) 
8. Rhodosporium rubrum NCIM 1689 (Gram negative) 
Fungus 
1. Monascus purpureus MTCC 1090 
2. Aspergillus niger NCIM 1207 
3. Candida albicans MTCC 3100 
4. Trichophyton rubrum MTCC 3272 
 
6.1.1a. Antibacterial screening 
The antibacterial activities of synthesized compounds were screened in the 
concentration of 1mg/ml in dimethyl sulphoxide against the above mentioned bacteria 
in the Muller Hinton agar medium by Disc diffusion method
 
using ciprofloxacin 5µg as 
standard. The antibacterial activity was evaluated by measuring zone of inhibition in 
mm. The procedure is given below. 
PROCEDURE 
Preparation of Nutrient Broth for Bacteria 
Ingredients used  
Sr. No Ingredients Quantity 
1 Beef extract 10g 
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2 Peptone 10g 
3 Sodium chloride 5g 
4 Water 1000ml 
 
The accurately weighed quantity of above ingredients were transferred to a 
conical flask, and dissolved in distilled water with the aid of heat with stirring and the 
pH was adjusted to 7.2 – 7.4 and plugged with non-absorbent cotton, covered by 
Aluminium foil and sterilized by autoclaving (121˚C at 15 lbs pressure for 15 min). 
 
Preparation and standardization of inoculation 
Each bacterial pure culture from the slant culture is picked up aseptically and 
was transferred into 100 ml of nutrient broth. The inoculated broths were incubated at 
37˚C for 24 hrs and growth was arrested by stored in the refrigerator (below 4˚C). 
Sample Preparation 
1 mg of each sample was dissolved in 1ml DMSO (Dimethyl Sulfoxide) to a 
final concentration of 1µg/ml. The solvent control shows no antibacterial activity with 
all the test organisms used. The sterile disc (6 mm in diameter) were impregnated with 
10 µg/disc of the sample and tested against microbial cultures. 
Media Used 
Muller – Hinton Agar Medium, Hi-media India (Pvt) Ltd 
Muller Hinton agar medium was prepared and transferred into sterile petri plates 
aseptically (thickness of 5-6mm). The plates were allowed to dry at room temp. The 
plates were inverted to prevent condensate falling on the agar surface. The layers of the 
medium are uniform in thickness, is done by placing the plates on a leveled surface. 
Standardized bacterial inoculums were applied to the plates and spreaded uniformly 
over the surface of medium by using a sterile Non-absorbent cotton swab and finally 
the swab was passed around the edge of the medium. The inoculated plates were closed 
with the lid and allowed to dry at room temperature. The sample impregnated discs 
were placed on the inoculated agar medium. All Petri plates were incubated at 37˚C for 
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24 hrs. After the incubation diameter of zone of inhibition produced by the sample were 
measured. 
The results were tabulated in the table 6.1& 6.2. 
6.1.1b. Antifungal screening 
The antifungal activities of synthesized compounds were screened in the 
concentration of 1 mg/ml in dimethyl sulphoxide against the above mentioned fungus in 
the Sabourand’s Dextrose Broth by Disc diffusion method using Clotrimazole 5 µg. The 
antifungal activity was evaluated by measuring zone of inhibition in mm. The 
procedure is given below.  
 
PROCEDURE 
Preparation of Nutrient Broth for Bacteria 
Ingredients used  
 
S.No Ingredients Quantity 
1 Dextrose 40g 
2 Peptone 10g 
3 Water 1000ml 
 
Specified amount of dextrose and peptone was taken along with 1000ml of 
distilled water in a conical flask and heated in a steam bath to dissolve. The pH was 
maintained at 7.6 ± 0.2 and sterilized in an autoclave at 15 lb pressure, 120°C for 15 
minutes. The sterile medium was poured into the sterile Petri dish and allowed to 
solidify.  
 
Preparation and standardization of inoculums  
Each fungal pure culture from the slant culture is picked up aseptically and was 
transferred into 100ml of nutrient broth. The inoculated broths were incubated at 27˚C-
28˚C for 24-48 hrs and growth was arrested by stored in the refrigerator (below 4˚C). 
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Sample Preparation 
1mg of each sample was dissolved in 1ml DMSO (Dimethyl Sulphoxide) to a 
final concentration of 1μg/ml. The solvent control shows no antibacterial activity with 
all the test organisms used. The sterile disc (6 mm in diameter) were impregnated with 
10μg/disc of the sample and tested against microbial cultures. 
 
Media Used 
Media used Sabouraud’s Dextrose Broth, Hi-media India (Pvt) Ltd 
Sabouraud’s dextrose broth medium was prepared and transferred into sterile 
Petri plates aseptically (thickness of 5-6mm). The plates were allowed to dry at room 
temp. The plates were inverted to prevent condensate falling on the agar surface. The 
layers of the medium are uniform in thickness, is done by placing the plates on a 
leveled surface. Standardized bacterial inoculums were applied to the plates and 
spreaded uniformly over the surface of medium by using a sterile Non-absorbent cotton 
swab and finally the swab was passed around the edge of the medium. The inoculated 
plates were closed with the lid and allowed to dry at room temperature. The sample 
impregnated discs were placed on the inoculated agar medium. All Petri plates were 
incubated at 27˚C -28˚C for 24 hrs. After the incubation diameter of zone of inhibition 
produced by the sample were measured.  
The results were tabulated in the table 6.5. 
 
6.1.2 MINIMUM INHIBITORY CONCENTRATION (MIC) 
 The lowest concentration of the test compound that completely inhibited growth 
on agar plates, disregarding a single colony or a faint haze caused by the inoculums was 
considered as minimum inhibitory concentration (MIC) of that compound.  
The potency of drug is based on inhibition of microbial growth as indicated by 
measurement of turbidity of a suspension of a suitable microorganism in a fluid 
medium to which graded amount of test compound have been added. The changes in 
turbidity produced by known concentration of reference materials are compared with 
results. 
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Determination of Minimum Inhibitory Concentration for Synthesized Compounds 
(MIC) by serial dilution Method: 
 
1. The serial dilutions of known concentration of compound solution were 
made from the stock (0.1mg/ml) by using Muller Hinton broth using the 
method described below. 
2. The tubes were labelled 1 to 8 and 1 ml of Muller Hinton broth were added 
to the first 5 tubes and 8
th
 tube, then added 0.5 ml Muller Hinton broth to 6
th
 
and 7
th
 tubes. 
3. One ml of different synthesized compounds was added to the 1st tube, mixed 
and transfers 1 ml serially up to tube 5. From the 5
th
 tube transfer 1ml to 6
th
 
tube. Mixed and transfer 0.5 ml to the 7
th
 tube. Each tube, 1 to 7 contains 
1ml diluted extract. 
4. 8th tube was the control. 
5. With a standardized micro pipette, added a drop of the diluted broth culture 
approximately 0.01ml of the test organism to all tubes, including the control, 
gently mixed and incubated at 37
 0
C for 16 to 18hrs. 
6. The highest dilution of particular compounds showing no turbidity was 
observed and recorded. This was taken as the end point, and this dilution 
was considered to contain the concentration of drug equivalent to MIC.  
The results were tabulated in the table 6.3, 6.4, 6.6. 
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6.2 IN- VITRO ANTI MALARIAL SCREENING: 
CANDLE JAR METHOD 
(87)
 
PROCEDURE  
Preparation of Serum: 
 Fresh human whole blood (preferably O+ or A+) was collected in a blood 
collection bags without anticoagulant. The blood was transferred (before clotting 
occurs) to the sterile 50ml centrifuge tubes. (In a laminar flow cabinet) 
 The blood was stored overnight at 4oC to allow clotting. 
 The serum and erythrocytes is fractionated by centrifugation. (2500 rpm for 
30mins at room temperature) 
 The serum was then transferred under sterile conditions to new sterile 50ml tubes. 
 The serum was inactivated by incubation in a water bath for 20mins at 65oC. 
 The serum was then stored at -20oC in the 50ml sterile tubes. 
 
P.falciparum culture: Media and Buffers (Serum): 
The medium used for culturing of Plasmodium falciparum was prepared as follows: 
Ingredients used 
 S.NO                   INGREDIENTS          QUANTITY 
    1              RPMI-1640(sigma)               10.4g 
    2         HEPES (sigma, cell culture tested)               5.94g 
    3      D-glucose (sigma, cell culture tested)               4.0g 
    4    Hypoxanthine(sigma, cell culture tested)               44mg 
    5                     Gentamycin               0.4ml 
    6                   Distilled water             1000ml 
 
             The accurately weighed quantities of the above ingredients were transferred 
into the conical flask, mixed well and leave for 30 minute at room temperature. Add 
36ml of 5% NaHCO3 solution was added to the medium to buffer the solution at pH 
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of 7.4. The solution was filtered using a sterile Millipore filters (0.22mm). Filtered 
solution was divided into two half’s. Transferred half to the 500ml   medium bottle 
and stored at 4
o
C (wash medium). 50ml human serum was added to the other half and 
transferred to a 500ml medium bottle and stored at 4
0
C(culture medium). 
Preparation of Erythrocytes: 
 Erythrocytes were collected in a 10ml vacationer (vacutest) tubes with 
anticoagulant (EDTA purple). 
 The blood was transferred under sterile conditions to the sterile 10ml 
centrifuge tube. 
 It was centrifuged to separate the cells and serum (2500 rpm for 5mins at 
room temperature). 
 The serum and “Buffy-coat” was aspirated using a Pasteur pipette fixed to the 
vacuum line. 
 The volume was then supplemented to 10ml with “wash medium” and mixed 
well. 
 The cells were centrifuged (2500 rpm for 5mins at room temperature). 
 Steps 4 to 6 were repeated another two times. 
 The washed erythrocytes was resuspended in wash medium and stored at 4oC. 
Cultivation of Parasites: 
         Preheat the culture medium by placing it in the 37
o
C water bath or in the 
incubator. 0.5ml of culture medium, 20µl of washed erythrocytes and 20µl of 
P.falciparum infected human blood were placed in 96 well plates. The well plates 
were placed in a candle jar and incubated at 37
o
C for 24hrs. Parasite count was 
made on giemsa stained thin smears. 
 Preparation of thin smears: 
 A small amount of erythrocytes were removed using a Pasteur pipette and 
placed on a microscopic slide. The second slide was placed on the first and 
moves it back into the drop, spreading it. The second slide was then 
moved forward, smearing a film of blood across the first slide. 
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 The smear was allowed to dry, and then it was fixed with methanol. 
 The methanol was discarded and the slide was covered with giemsa 
stained solution for 3 to 5 minutes to stain. (The giemsa solution consists 
of approximately 0.5ml phosphate buffer and 10-20 drops of concentrated 
giemsa stock solution). Then rinsed with water and allowed it to dry, 
where after it was studied microscopically (100x). 
 Parasitemia were counted by counting both uninfected and parasite 
infected erythrocytes. 
 Expressing the parasite count as a percentage of infected erythrocytes as 
per total erythrocyte count. 
Interpretation of microscopic slides: 
             Different stages of malaria parasite in the red blood cells interpreted. 
 
Uninfected erythrocytes 
                                
Infected erythrocytes 
             Different stages of the malarial parasite in the red blood cells. 
 Ring: 
                   
Early Trophozoite: 
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Trophozoite: 
             
Transition Stage: 
                 
Anti-Plasmodial activity of the synthesized compounds: 
              Various concentrations of the synthesized compounds and standard drug 
pyremethamine (20,40,60,80 µg/ml) in DMSO, was added to the well plates containing 
0.5ml of culture medium, 20 µl of washed erythrocytes and 20 µl of P.falciparum 
infected human blood. Well plates were placed in the candle jar and incubated at 37
o
C for 
24hrs. Parasite count were made on the giemsa stained thin smears prepared at different 
time intervals (24, 48, 72 hrs). And in-vitro anti-plasmodial activity of the synthesized 
compounds was determined by calculating inhibitory concentration percentage. 
 Percentage can be calculated using the formula, 
IC50= No of parasitemia in control – No of parasitemia in treated × 100 
                               No of parasitemia in control 
The results were tabulated in the table 6.7. 
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O2N N
.
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N
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H
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DPPH
(REDUCED FORM)
FREE
RADICAL
6.3 IN-VITRO ANTI-OXIDANT SCREENING OF SYNTHESIZED COMPOUNDS
 
 In-vitro anti-oxidant screening of synthesized compounds were done by using 
three methods  
 DPPH method 
 FRAP method  
 ABTS method 
6.3.1 DPPH RADICAL SCAVENING ACTIVITY: 
(88) 
PRINCIPLE: 
DPPH molecule a stable free radical by its nature of delocalization of  unpaired 
electron which gives rise to the deep violet color which was characterized by an 
absorption at about 519 nm. When solution of DPPH (diphenylpicrylhydrazyl) mixed with 
that of a substance that can donate an electron (i.e. an antioxidant) it is converted to its 
reduced form with the loss of this violet color to pale yellow color. The primary 
reaction involved in this assay is given below
. 
 
                                                       Z
.
 +AH=ZH+A
. 
Where,
 
Z.   -DPPH radical 
AH -Donor molecule 
ZH -Reduced form 
A.   -Free radical  
The result of the antioxidant efficiency is expressed as EC50, determined as the 
concentration of substrate that causes 50% loss in absorbance. 
 
Reaction: 
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REAGENTS: 
Radical          : DPPH 
Solvent          : Ethanol 
Standard        : Ascorbic acid 
 
Preparation of 0.3 mm DPPH solution: 
It was prepared by dissolving DPPH (5.91 mg) in 50ml of methanol. This stock 
solution was prepared freshly and kept in the dark at ambient temperature when not 
used. 
Preparation of Sample Stock Solution: 
The sample stock solution was prepared by dissolving the compound in suitable 
solvent (Ethanol) with a final concentration of 1mg/ml. 
Preparation of Standard Stock Solution: 
The standard stock solution was prepared by dissolving the Ascorbic acid   in 
suitable solvent (Ethanol) with a final concentration of 1mg/ml. 
 PROCEDURE: 
All the compound anti oxidant were screening by DPPH assay method, Sample 
stock solutions (1.0 mg/ml) were diluted to final concentrations of 10, 20, 40, 60, 80, 100 
μg/ml, in ethanol. An ethanolic solution of 1ml of DPPH (0.3mM) was added to 0.5ml of 
the compound and allowed to react at room temperature in a dark place for 30 minutes. 
After 30 minutes the absorbance values were measured at 519 nm. All the measurements 
were taken as a triplicate values from the average of the absorbance values; Lower 
absorbance of the reaction mixture indicates higher free radical scavenging activity. The 
antioxidant scavenging activity of the DPPH radical was calculated according to the 
following equation. 
                             
    % inhibition = (ABS control – ABS test) /ABS control × 100 
Where, 
Control-Absorbance of ethanol+DPPH 
Test     -Absorbance of DPPH + Compound /Standard 
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The percentage antioxidant activity (Percentage inhibition) was extrapolated against 
concentration of the Compound 
The results were tabulated in the table 6.8. 
6.3.2 FRAP (Free Radical scavenging activity) ASSAY:
 (89) 
Total antioxidant activity is measured by ferric reducing antioxidant power (FRAP) assay 
of Benzie and Strain (1999). FRAP assay uses antioxidants as reductants in a redox-
linked colorimetric method, employing an easily reduced oxidant system present in 
stoichiometric excess.  
Principle  
At low pH, reduction of ferric tripyridyl triazine (Fe III TPTZ) complex to ferrous form 
(which has an intense blue color) can be monitored by measuring the change in 
absorption at 593nm. The reaction is non-specific, in that any half reaction that has lower 
redox potential, under reaction conditions, than that of ferric ferrous half reaction, will 
drive the ferrous (Fe III to Fe II) ion formation. The change in absorbance is therefore, 
directly related to the combined or “total” reducing power of the electron donating 
antioxidants present in the reaction mixture.  
Reagents  
FRAP Reagent  
a) Acetate buffer 300 mM pH 3.6: Weigh 3.1g sodium acetate trihydrate and add 16 ml of 
glacial acetic acid and make the volume to 1 L with distilled water.  
b) TPTZ (2, 4, 6-tripyridyl-s- triazine) (M.W. 312.34) 10 mM in 40mM HCl (M.W. 
36.46)  
c) FeCl3. 6H2O (M.W. 270.30) 20 mM  
The working FRAP reagent was prepared by mixing a b & c in the ratio of 10:1:1 at the 
time of use.  
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Standard: Ascorbic Acid (M.W. 176.13) 1000 µ M  
Procedure  
The reaction mixture contained 900 l of freshly prepared FRAP reagent and it was 
added to different concentrations of test solution. Finally volume was made to 1ml with 
ethanol. The blank solution was prepared by mixing 900 l FRAP reagent and 100 l of 
methanol. Measured the absorbance at 593 nm, just after 4 minutes from the time of 
addition of FRAP reagent. An increase in absorbance indicated enhanced reducing 
potential of plasma. Quantitative calculation for each sample was done using an equation 
obtained from the standard curve of Fe++-TPTZ. 
The equation used:  Absorbance = 0.274 x M of Fe++ + 0.114 [R2 = 0.974]  
The results were tabulated in the table 6.9. 
6.3.3 ABTS Radical scavenging activity:
 (90)
 
 Reagents 
 2.45 mM ammonium persulphate 
 7 mM 2,2,-azinobis (3-ethylbenzoline-6-sulfonic acid) (ABTS) 
Procedure 
The ABTS radical scavenging activity of the extract was measured by Rice-Evans et al., 
(1997). ABTS radical cation (ABTS+
.
) was produced by reacting 5ml of 14mM ABTS 
solution with 5ml of 4.9mM ammonium persulphate solution and the mixture was 
allowed to stand in dark place at room temperature for 12-16 hr before use. The mixture 
was diluted with water to yield an absorbance of 0.7±0.02 at 734nm. Different 
concentrations (1-10 µg/ml) of Methanolic extract of test solution or standard (Quercetin) 
were added to 950l of ABTS radical solution and the final volume was made up to 1ml 
with methanol. The blank solution was prepared by mixing 950l ABTS solution and 
50l methanol. After 6 minutes the absorbance was read at 734nm and the percentage 
inhibition was calculated. The experiment was performed in triplicate.
41
. The scavenging 
activity of ABTS radical was calculated by using the following equation. 
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                                                               A control – A test 
                              % inhibition =                                    X 100 
                                                                     A control 
Where A control was the control absorbance and A test was the sample absorbance in the 
presence of synthesized compound.  
The results were tabulated in the table 6.10. 
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6.4 IN-VITRO ANTI-CANCER SCREENING: 
(91, 92)
 
The human hepatic carcinoma cell line (HepG2) was obtained from National Centre for 
Cell Science (NCCS), Pune, and grown in Eagles Minimum Essential Medium containing 
10% fetal bovine serum (FBS). All cells were maintained at 37
0
C, 5% CO2, 95% air and 
100% relative humidity. Maintenance cultures were passaged weekly, and the culture 
medium was changed twice a week. 
Cell treatment procedure 
 The monolayer cells were detached with trypsin-ethylenediaminetetra acetic acid 
(EDTA) to make single cell suspensions and viable cells were counted using a 
hemocytometer and diluted with medium with 5% FBS to give final density of 1x10
5
 
cells/ml. one hundred microlitres per well of cell suspension were seeded into 96-well 
plates at plating density of 10,000 cells/well and incubated to allow for cell attachment at 
37
0
C, 5% CO2, 95% air and 100% relative humidity. After 24 h the cells were treated 
with serial concentrations of the extracts and fractions. They were initially dissolved in 
neat dimethyl sulfoxide (DMSO) and further diluted in serum free medium to produce 
five concentrations. One hundred microlitres per well of each concentration was added to 
plates to obtain final concentrations of 100, 10, 1.0 and 0.1µM. The final volume in each 
well was 200 µl and the plates were incubated at 37
0
C, 5% CO2, 95% air and 100% 
relative humidity for 48h. The medium containing without samples were served as 
control. Triplicate was maintained for all concentrations. 
MTT assay 
 MTT is a yellow water soluble tetrazolium salt. A mitochondrial enzyme in living 
cells, succinate-dehydrogenase, cleaves the tetrazolium ring, converting the MTT to an 
insoluble purple formazan. Therefore, the amount of formazan produced is directly 
proportional to the number of viable cells. 
 After 48h of incubation, 15µl of MTT (5mg/ml) in phosphate buffered saline 
(PBS) was added to each well and incubated at 37
0
C for 4h. The medium with MTT was 
then flicked off and the formed formazan crystals were solubilized in 100µl of DMSO 
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and then measured the absorbance at 570 nm using micro plate reader. The % cell 
inhibition was determined using the following formula.  
% cell Inhibition = 100- Abs (sample)/Abs (control) x100.  
 The results were tabulated in the table 6.11, 6.12, 6.13, 6.14. 
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Table 6.1: In -Vitro Antibacterial Activity (Gram Positive Strains) Data in Zone Of Inhibition (Mm) and 
Percentage Inhibition by Disc Diffusion Method  
 
 
 
*Ciprofloxacin  
 
Organism 
Diameter of zone of inhibition (mm) / percentage of inhibition 
DPN-1 DPN-2 DPN-3 DPN-4 DPN-5 DPN-6 DPN-7 DPN-8 DPN-9 DPN-10 DPN-11 DPN-12 DPN-13 DPN-14 DPN-15 STD 
* 
Micrococus  
leutus 
08 
(26.67%) 
08 
(26.67%) 
09 
(29.97%) 
12 
(39.96%) 
12 
(39.96%) 
12 
(39.96%) 
24 
(79.92%) 
24 
(79.92%) 
12 
(39.96%) 
14 
(46.62%) 
24 
(79.92%) 
18 
(46.62%) 
20 
(66.67%) 
12 
(39.96%) 
08 
(26.67%) 
30 
Staphylococcus 
aureus 
10 
(35.71%)  
14 
(49.98%) 
14 
(49.98%) 
10 
(35.71%) 
10 
(35.71%) 
10 
(35.71%) 
24 
(85.71%) 
24 
(85.71%) 
12 
(42.85%) 
10 
(35.71% 
24 
(85.71%) 
12 
(42.85%) 
10 
(35.71% 
10 
(35.71% 
07 
(24.99%) 
28 
Baccilus substills 07 
(26.92%) 
12 
(46.15%) 
11 
(42.31%) 
11 
(42.31%) 
12 
(46.15%) 
12 
(46.15%) 
18 
(69.23%) 
18 
(69.23%) 
12 
(46.15%) 
12 
(46.15%) 
18 
(69.23%) 
14 
(53.84%) 
12 
(46.15%) 
14 
(53.84%) 
07 
(26.92%) 
26 
Corynebacterium - 13 
(74.88%) 
14 
(58.33%) 
12 
(50.00%) 
11 
(45.83%) 
12 
(50.00%) 
18 
(74.88%) 
19 
(79.04%) 
12 
(50.00%) 
12 
(50.00%) 
18 
(74.88%) 
14 
(58.33%) 
12 
(50.00%) 
14 
(58.33%) 
- 24 
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*Ciprofloxacin  
Fig 6.1: Graphical Representation of In-Vitro Anti-Bacterial (Gram Positive) activity  
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Table 6.2: In-Vitro Antibacterial Activity (Gram Negative Strains) Data in Zone Of Inhibition (Mm) and 
Percentage Inhibition by Disc Diffusion Method 
 
 
 
Organism 
Diameter of zone of inhibition (mm) / percentage of inhibition 
DPN-1 DPN-2 DPN-3 DPN-4 DPN-5 DPN-6 DPN-7 DPN-8 DPN-9 DPN-10 DPN-11 DPN-12 DPN-13 DPN-14 DPN-15 STD 
* 
Escherichia 
coli 
08 
(33.28%) 
10 
(41.63%) 
10 
(41.63%) 
12 
(50.00%) 
11 
(45.83%) 
12 
(50.00%) 
16 
(66.56%) 
17 
(70.72%) 
08 
(33.28%) 
10 
(41.63%) 
16 
(66.56%) 
10 
(41.63%) 
10 
(41.63%) 
10 
(41.63%) 
- 24 
Pseudomonas 
aeruginosa 
- 14 
(49.98%) 
14 
(49.98%) 
10 
(35.71%) 
10 
(35.71%) 
09 
(32.14%) 
20 
(71.42%) 
20 
(71.42%) 
08 
(28.57%) 
12 
(42.85%) 
20 
(71.42%) 
12 
(42.85%) 
10 
(35.71%) 
10 
(35.71%) 
08 
(28.57%) 
28 
Rhodospirillum 
rubrum 
10 
(55.56%) 
14 
(77.78%) 
10 
(55.56%) 
08 
(44.44%) 
10 
(55.56%) 
12 
(66.67%) 
14 
(77.78%) 
14 
(77.78%) 
12 
(66.67%) 
11 
(61.11%) 
14 
(77.78%) 
10 
(55.56%) 
12 
(66.67%)  
14 
(77.78%) 
09 
(50.00%) 
18 
Vibrio cholerae 10 
(50.00%) 
12 
(60.00%) 
13 
(65.00%) 
14 
(70.00%) 
14 
(70.00%) 
14 
(70.00%) 
14 
(70.00%) 
15 
(75.00%) 
10 
(50.00%) 
10 
(50.00%) 
14 
(70.00%) 
12 
(60.00%) 
08 
(40.00%) 
12 
(60.00%) 
- 20 
 
*Ciprofloxacin  
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FIG 6.2: Graphical Representation of In-Vitro Anti-Bacterial (Gram negative) activity  
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Table 6.3: In -Vitro Antibacterial Activity (Gram Positive Strains) Data in Minimum Inhibitory 
Concentration 
 
 
 
*Ciprofloxacin  
 
 
 
 
Organism 
MIC µg\ml 
DPN-1 DPN-2 DPN-3 DPN-4 DPN-5 DPN-6 DPN-7 DPN-8 DPN-9 DPN-10 DPN-11 DPN-12 DPN-13 DPN-14 DPN-15 
Micrococus  leutus 100  100  50  50  50  50  12.5  12.5  50  50  12.5  25  25  50  100  
Staphylococcus 
aureus 
50  50  50  50  50  50  12.5  12.5  50  50  12.5  50  50  50  100  
Baccilus substills 100  50  50 50  50  50  25  25  50  50  25  50  50  50  100  
Corynebacterium - 50  50  50  50  50  25 25  50  50  25  50  50  50  - 
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Table 6.4: In-Vitro Antibacterial Activity (Gram Negative Strains) Data in Minimum Inhibitory 
Concentration 
 
 
 
 
 
*Ciprofloxacin  
 
Organism 
MIC µg/ml 
DPN-1 DPN-2 DPN-3 DPN-4 DPN-5 DPN-6 DPN-7 DPN-8 DPN-9 DPN-10 DPN-11 DPN-12 DPN-13 DPN-14 DPN-15 
Escherichia coli 50  50  50  50  50  50  25  25  100  50  25  50  50  50  - 
Pseudomonas 
aeruginosa 
- 50  50  50  50  50  25  25  100  50  25  50  50  50  100  
Rhodospirillum 
rubrum 
50  50  50  100  50  50  50  50  50  50  50  50  50  50  100  
Vibrio cholerae 50  50  50 50  50  50  50  25  50  50  50  50  100  50  - 
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Table 6.5: In-Vitro Antifungal Activity Data in Zone Of Inhibition (Mm) and Percentage Inhibition by 
Disc Diffusion Method 
 
Organism 
Diameter of zone of inhibition (mm) / percentage of inhibition 
DPN-1 DPN-2 DPN-3 DPN-4 DPN-5 DPN-6 DPN-7 DPN-8 DPN-9 DPN-10 DPN-11 DPN-12 DPN-13 DPN-14 DPN-15 STD 
*
 
Candida 
albicans 
12 
(39.96%) 
12 
(39.96%) 
12 
(39.96%) 
12 
(39.96%) 
12 
(39.96%) 
12 
(39.96%) 
24 
(79.92%) 
24 
(79.92%) 
18 
(59.94%) 
14 
(46.62%) 
14 
(46.62%) 
16 
(53.32%) 
16 
(53.32%) 
10 
(33.33%) 
18 
(59.94%) 
30 
Monascus 
purpureus 
10 
(33.33%) 
10 
(33.33%) 
10 
(33.33%) 
12 
(39.96%) 
12 
(39.96%) 
12 
(39.96%) 
20 
(66.67%) 
20 
(66.67%) 
14 
(46.62%) 
12 
(39.96%) 
12 
(39.96%) 
12 
(39.96%) 
12 
(39.96%) 
10 
(33.33%) 
16 
(53.32%) 
30 
Aspergillus 
niger 
18 
(59.94%) 
16 
(53.32%) 
16 
(53.32%) 
18 
(59.94%) 
18 
(59.94%) 
18 
(59.94%) 
28 
(93.24%) 
28 
(93.24%) 
16 
(53.32%) 
24 
(79.92%) 
24 
(79.92%) 
22 
(73.26%) 
22 
(73.26%) 
20 
(66.67%) 
20 
(66.67%) 
30 
Trichophyto
n rubrum 
16 
(53.32%) 
14 
(46.62%) 
14 
(46.62%) 
18 
(59.94%) 
18 
(59.94%) 
18 
(59.94%) 
24 
(79.92%) 
24 
(79.92%) 
16 
(53.32%) 
22 
(73.26%) 
22 
(73.26%) 
22  
(73.26%) 
22 
(73.26%) 
22 
(73.26%) 
19 
(63.27%) 
30 
*Clotrimazole 
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FIG 6.3: Graphical Representation of In-Vitro Anti-Fungal activity  
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Table 6.6: In-Vitro Anti-Fungal Activity Data in Minimum Inhibitory Concentration 
 
 
 
 
*Clotrimazole 
 
 
 
Organism 
MIC µg\ml 
DPN-1 DPN-2 DPN-3 DPN-4 DPN-5 DPN-6 DPN-7 DPN-8 DPN-9 DPN-10 DPN-11 DPN-12 DPN-13 DPN-14 DPN-15 
Candida albicans 50 50 50 50 50 50 12.5 12.5 25 50 50 25 25 50 25 
Monascus 
purpureus 
50 
 
50 50 50 50 
 
50 12.5 12.5 50 50 50 50 50 50 25 
Aspergillus niger 25 50 50 25 25 25 6.25 6.25 50 12.5 12.5 12.5 12.5 25 25 
Trichophyton 
rubrum 
50 
 
50 
 
50 25 25 25 12.5 
 
12.5 50 25 25 25 25 25 25 
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Table 6.7: In vitro anti Plasmodial activity of synthesized compounds against plasmodium falciparum  
S.No 
Compound 
Code 
IC50 Values (%) 
Percentage Inhibition 
20 (µg/ml) 40    (µg/ml) 60 (µg/ml) 80 (µg/ml) 
1 DPN-03 28.46 36.15 41.53 43.84 
2 DPN-06 66.92 72.30 80.0 84.61 
3 DPN-08 74.61 80.0 82.30 87.69 
4 DPN-10 59.23 66.92 74.61 84.61 
5 DPN-11 72.30 74.61 80.0 87.69 
6 DPN-12 59.23 66.92 74.61 80.0 
7 DPN-13 36.15 41.53 43.84 49.23 
8 DPN-14 41.53 46.15 57.69 61.53 
9 STD* 72.30 80.15 87.69 95.32 
* Pyremethamine 
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Fig 6.4: Graphical Representation of In-Vitro anti Plasmodial activity 
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TABLE 6.8: IN-VITRO ANTI-OXIDENT ACTIVITY BY DPPH ASSAY METHOD 
 
 
*Ascorbic acid 
Compound 
code 
Concentration 
EC 50 
10μg 20μg 40μg 60μg 80μg 100μg 
DPN-01 15.95 22.28 19.56 23.51 36.73 32.23 - 
DPN-02 58.34 61.94 66.81 70.19 76.98 81.82 8.57 
DPN-03 59.4 62.46 68.42 72.23 77.71 82.36 8.14 
DPN-04 56.34 62.46 72.23 74.31 82.94 85.14 8.88 
DPN-05 58.49 62.97 73.32 78.65 83.23 87.03 8.57 
DPN-06 60.35 63.5 74.31 82.94 85.14 89.37 8.12 
DPN-07 40.28 54.89 68.19 90.20 95.64 96.94 18.21 
DPN-08 42.81 53.49 78.61 95.8 96.32 97.58 18.69 
DPN-09 52.84 65.67 80.18 90.79 95.34 97.58 9.46 
DPN-10 23.29 25.34 34.98 19.34 24.65 31.65 - 
DPN-11 42.81 53.49 63.35 79.73 83.92 87.61 18.69 
DPN-12 50.68 66.89 70.75 73.22 77.66 78.06 9.92 
DPN-13 60.66 66.01 83.92 87.61 89.72 93.28 8.24 
DPN-14 30.33 39.84 47.15 49.51 55.23 55.77 - 
DPN-15 23.12 32.56 34.49 33.87 39.51 40.99 - 
STD* 97.64 98.06 
 
98.64 99.03 99.25 99.65 5.12 
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Fig 6.5: Graphical Representation of In-Vitro Anti-Oxidant Activity by DPPH Assay Method 
0
10
20
30
40
50
60
70
80
90
100
DPN 
01
DPN  
02
DPN 
03
DPN 
04
DPN  
05
DPN 
06
DPN 
07
DPN 
08
DPN  
09
DPN 
10
DPN 
11
DPN 
12
DPN 
13
DPN 
14
DPN 
15
STD
100μg
200μg
400μg
600μg
800μg
1000μg
BIOLOGICAL SCREENING 
 
 
Department of Pharmaceutical Chemistry  129 
Table 6.9: IN-VITRO ANTI-OXIDENT ACTIVITY BY ABTS ASSAY METHOD 
 
 
*Ascorbic acid  
 
Compound 
code 
Concentration 
EC 50 
10μg 20μg 40μg 60μg 80μg 100μg 
DPN-01 59.4 62.46 68.42 72.23 77.71 82.36 8.41 
DPN-02 15.95 22.28 19.56 23.51 36.73 32.23 - 
DPN-03 16.99 18.28 19.56 23.51 30.73 33.23 - 
DPN-04 23.12 32.56 34.49 33.87 39.51 40.99 - 
DPN-05 30.33 39.84 47.15 49.51 50.12 52.77 - 
DPN-06 31.33 33.84 36.15 40.51 43.23 46.77 - 
DPN-07 58.49 62.97 73.32 78.65 83.23 87.03 8.56 
DPN-08 40.28 54.89 68.19 90.2 95.64 96.94 18.21 
DPN-09 24.12 31.56 33.49 34.87 38.51 42.99 - 
DPN-10 59.35 62.5 75.31 82.94 84.14 87.39 8.47 
DPN-11 23.12 32.56 34.49 33.87 35.51 44.99 - 
DPN-12 60.35 63.5 74.31 82.94 85.14 89.37 8.27 
DPN-13 30.33 39.84 47.15 49.51 55.23 55.77 - 
DPN-14 23.12 32.56 34.49 33.87 39.51 40.99 - 
DPN-15 15.95 22.28 19.56 23.51 36.73 32.23 - 
STD* 97.64 98.06 98.64 99.03 99.25 99.65 5.12 
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Fig6.5: Graphical Representation of In-Vitro Anti-Oxidant Activity by ABTS Assay Method 
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Table 6.9: In-Vitro Anti-Oxidant Activity By FRAP Assay Method 
 
*FERROUS SULPHATE 
Compound code 
Concentration 
R
2
 
20μg 40μg 60μg 80μg 100μg 
DPN-01 0.7513 0.7921 0.7576 0.7909 0.7848 - 
DPN-02 0.7192 0.7364 0.7776 0.8419 0.9298 0.934 
DPN-03 0.6992 0.7364 0.7776 0.8419 0.9298 0.965 
DPN-04 0.7513 0.7621 0.7776 0.7309 0.7141 - 
DPN-05 0.8513 0.8621 0.9776 0.9309 0.9141 - 
DPN-06 0.6513 0.6621 0.7776 0.6309 0.8141 - 
DPN-07 0.8222 0.6655 0.6974 0.8042 0.7431 - 
DPN-08 0.7222 0.7655 0.7974 0.8042 0.7431 - 
DPN-09 0.7992 0.8364 0.8776 0.9419 1.0298 - 
DPN-10 0.8736 0.9605 0.9909 1.066 1.1081 0.98 
DPN-11 1.3417 1.4412 1.6059 1.7892 1.8472 0.978 
DPN-12 0.8736 0.9605 0.9909 1.066 1.1081 0.98 
DPN-13 0.8857 0.7327 0.8584 0.7331 0.9572 - 
DPN-14 0.9525 1.0179 1.1928 1.244 1.3869 0.975 
DPN-15 0.6052 0.7547 0.8658 0.7386 0.7452 - 
STD* 1.0447 1.403 1.6617 1.9034 2.2443 0.995 
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IN-VITRO ANTI-CANCER SCREENING 
TABLE 6.11: HepG2 cell line inhibition by the compound DPN 03 
Conc (µM) 
% Cell 
Inhibition Conc 0.1 µM 1 µM 10 µM 100 µM 
0.1 3.548896 ABS 0.402 0.388 0.365 0.355 
1 8.359621  0.402 0.379 0.369 0.356 
10 13.24921  0.419 0.395 0.366 0.361 
100 15.45741 Avg 0.407667 0.387333 0.366667 0.357333 
 
TABLE 6.12: HepG2 cell line inhibition by the compound DPN 06 
Conc (µM) 
% Cell 
Inhibition Conc 0.1 µM 1 µM 10 µM 100 µM 
0.1 1.419558 ABS 0.4 0.409 0.395 0.383 
1 3.864353  0.416 0.428 0.414 0.4 
10 4.810726  0.434 0.382 0.398 0.383 
100 8.044164 Avg 0.416667 0.406333 0.402333 0.388667 
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TABLE 6.13:  HepG2 cell line inhibition by the compound DPN 08 
Conc (µM) 
% Cell 
Inhibition Conc 0.1 µM 1 µM 10 µM 100 µM 
0.1 4.022082 ABS 0.41 0.384 0.364 0.342 
1 10.41009  0.406 0.374 0.352 0.349 
10 15.77287  0.401 0.378 0.352 0.349 
100 17.98107 Avg 0.405667 0.378667 0.356 0.346667 
 
TABLE 6.14: HepG2 cell line inhibition by the compound DPN 11 
Conc (µM) 
% Cell 
Inhibition Conc 0.1 µM 1 µM 10 µM 100 µM 
0.1 8.753943 ABS 0.38 0.365 0.339 0.329 
1 14.27445  0.388 0.368 0.359 0.321 
10 16.64038  0.389 0.354 0.359 0.321 
100 23.42271 Avg 0.385667 0.362333 0.352333 0.323667 
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At concentration 100μm 
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RESULTS AND DISCUSSION: 
CHEMISTRY 
In the present work 15 different Schiff bases were synthesized in 6 steps by 
conventional method. 
Series I - Conventional method 
In the present work 15 different Schiff bases were synthesized in 6 steps. 
 Resacetophenone (FD1) was synthesized by heating the mixture of zinc chloride 
and glacial acetic acid with resorcinol at 120
0
C, then temperature was raised 142
o
C 
for 20 minutes.  
 4-acetylbenzene-1, 3-diyl bi (4-nitrobenzoate) (FD 2) was synthesized by refluxing 
resacetophenone with p-nitrobenzoyl chloride in presence of potassium carbonate 
and acetone for 6 hours. 
  3-hydroxy-4-[3-(4-nitrophenyl)-3-oxopropanoyl] phenyl 4-nitro benzoate (FD 3) 
was synthesized by stirring  4-acetylbenzene-1, 3-diyl bis (4-nitrobenzoate) with 10 
% glacial acetic acid for 30 minutes. 
 7-hydroxy-2-(4-nitrophenyl)-4H-chromen-4-one (FD 4) was synthesized from 3-
hydroxy-4-[3-(4-nitrophenyl)-3-oxopropanoyl] phenyl 4-nitro benzoate by 
refluxing them with glacial acetic acid and sodium acetate for 3 hours. 
 7-hydroxy-2-(4-aminophenyl)-4H-chromen-4-one (FD 5) was obtained from 
heating  7-hydroxy-2-(4-nitrophenyl)-4H-chromen-4-one with Tin Chloride and 
conc. HCl for 1 hour. 
 Finally 7-hydroxy-2-(4-Substituted amino phenyl)-4H-chromen-4-one (DP 1-15) 
is synthesized from 7-hydroxy-2-(4-aminophenyl)-4H-chromen-4-one by refluxing 
with aryl carbonyl compounds in presence of ethanol for 3 hrs. 
Yield of the derivatives were in the range of 52- 85%. Purity of all the newly compounds 
were checked by melting point and TLC Analysis and the structures were confirmed by 
UV, IR, NMR and MASS spectral data. 
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Series II – Microwave Irradiation method 
In the present work 8 different Schiff bases were synthesized in 4 steps by microwave 
irradiation method. 
 
 (E)-1-(2, 4-dihydroxyphenyl)-3-(4-nitrophenyl) prop-2-en-1-one(FM 1) was 
synthesized from resacetophenone with p-nitro benzaldehyde  in the presence of 
sodium hydroxide with ethanol and heated on water bath  resulting product was 
acetified  with HCl. 
 7-hydroxy-2-(4-nitrophenyl)-4H-chromen-4-one (FM 2) was obtained by 
irradiating the compound FM 1 with DMSO/I2 in Micro oven. 
 7-hydroxy-2-(4-aminophenyl)-4H-chromen-4-one (FM 3) is obtained from heating  
7-hydroxy-2-(4-nitrophenyl)-4H-chromen-4-one (FM 2) with Tin Chloride and 
conc. HCl for 1 hour. 
 7-hydroxy-2-(4-Substituted amino phenyl)-4H-chromen-4-one (MWD 1-8) was 
obtained by irradiating the compound (FM 3) with equal mole aromatic aldehydes 
& ketones for an optimized time. 
Yield of the derivatives were in the range of 94- 98%. Purity of all the newly 
compounds were checked by melting point and TLC Analysis and the structures were 
confirmed by UV, IR spectral data. 
 
DETERMINATION OF PHYSICOCHEMICAL PROPERTIES OF 
SYNTHESIZED COMPOUNDS 
MELTING POINT ANALYSIS  
Melting points of all the newly synthesized compounds were checked and 
uncorrected and the values were given in Table: 1&2. 
THIN LAYER CHROMATOGRAPHY ANALYSIS 
The reaction time for all the compounds were determined by running TLC and a 
single spot was obtained. Rf Values of all the newly synthesized compounds were 
checked and were tabulated in Table: 1&2.  
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SOLUBILITY 
Solubility was checked for all the newly synthesized compounds and found that all 
the compounds were soluble in benzene and DMSO. 
CHARACTERIZATION 
INFRARED SPECTRAL ANALYSIS 
 The lead compound FD 5 showed the absorption band at 3116 cm-1 due to the 
presence of –OH at 7th position of flavanoid ring and 1108 cm-1 due to ether linkage 
(C-O-C). A peak at 1540 cm
-1
 indicates the presence of primary amine and 1693 
cm
-1
  due to keto group (C=O). 
   
 
 All the Schiff base derivative compounds showed the characteristic peaks in the 
region 3200-3100 cm
-1 
for associated hydroxyl group, 840- 790 cm
-1
 for Ar, 
CH=CH stretching, 1640-1620 cm
-1
 , 1300-1050 cm
-1
 ether linkage (C-O-C stretch) 
and 1600-1400cm
-1
for C=O stretching. Compound DPN 7, DPN 8 containing NO2 
group showed absorption bands at 1550-1500, for the N=O stretching. The peak at 
716-808 cm
-1 
could be assigned to C-Cl stretching in the compound DPN 4, 5, 6. 
 
NUCLEAR MAGNETIC RESONANCE SPECTRAL ANALYSIS 
 The structures of the new compounds were confirmed by 1H-NMR spectra. All the 
synthesized compounds showed multiplets in the range δ 8.0-8.4 for the protons of 
aromatic ring. The spectrum of FD 05 revealed a singlet at δ 3.3 which may be 
assigned to NH2 proton.  
 The amino group of synthesized shown the broad singlet signals at 3.308 ppm, 
which were assigned to the N–H protons.  Phenolic OH proton of compounds 
exhibited singlets at13.4 ppm. Ethenyl proton adjacent to C=O (=CH (C=O) 
exhibited singlets at 12.18 ppm 
 
 Compounds exhibited Multiplet, signals at 7.42-7.79 ppm, and 8.29-8.42 ppm 
which was assigned to the benzopyran ring is present in compound. The phenyl 
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group of shown the doublet signals at 6.95-6.99 ppm, which were assigned to the 
phenyl group at second position of benzopyran ring.  
MASS SPECTRAL ANALYSIS 
 Electron impact mass spectral analysis was carried out on two randomly selected 
compounds FD 05, DPN 06, DPN 08 and DPN 11. Mass spectrums of the 
compounds were in full agreement with their molecular weights. 
BIOLOGICAL EVALUATION 
In-Vitro Anti-Bacterial Studies 
All the newly synthesized compounds were screened for preliminary antibacterial 
activity against both gram positive and gram negative bacteria by Disc diffusion method 
and determination of Minimum inhibitory concentration (MIC) by serial dilution 
method. 
All the newly synthesized compounds were screened for preliminary antibacterial 
activity at 100µg/disc concentration level by Disc diffusion. The results were compared 
with the standard drug (Ciprofloxacin) at 5µg/disc concentration level. 
All the synthesized compounds were shown mild to moderate activity against all the 
screened bacterial strains. Among the tested gram positive bacterial strains, all the 
synthesized compounds were shown more activity against corny bacterium with the 
percentage of inhibition range from 50-79%.  
Among the synthesized compounds, compounds DPN 07, DPN 08 and DPN 11 
shown better antibacterial activity than the other synthesized compounds with the 
percentage of inhibition range from 50-79%. MIC results were shown that most of the 
synthesized compounds have MIC range from 50 &100 μg/ml concentration levels 
against tested gram positive bacterial strains. 
  The  newly synthesized compounds DPN 07, DPN 08 and DPN 11 were shown 
MIC  value was found to be  12.5 and 25 μg/ml concentration levels against Micrococcus 
luteus, Staphylococcus aureus and Bacillus subtilis, Corny bacterium respectively. 
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Among the tested gram negative bacterial strains, all the synthesized compounds at 
100μg/disc concentration were shown more activity against Rhodospirillum rubrum and 
Vibrio cholerae the percentage of inhibition range from 50-78%.  
Among the synthesized compounds, compounds DPN 07, DPN 08 and DPN 11 
shown better antibacterial activity than the other synthesized compounds with the 
percentage of inhibition range from 67-78%. Most of the synthesized compounds show 
MIC value at 50 μg/ml concentration levels.  
The newly synthesized compounds DPN 07, DPN 08 and DPN 11 were shown MIC  
value at 25 and 50 μg/ml concentration levels against Escherichia coli ,Pseudomonas 
aeruginosa and Rhodospirillum rubrum, Vibrio cholerae   respectively. 
All the compounds screened shown better activity against gram negative bacteria 
than gram positive bacteria.  
 
In-Vitro Anti-Fungal Studies 
All the newly synthesized compounds were screened for preliminary antifungal 
activity by disc diffusion method and determination of Minimum inhibitory 
concentration (MIC) was done by serial dilution method. 
 
All the newly synthesized compounds were screened for preliminary antifungal 
activity at 100µg/disc concentration level by Disc diffusion. The results were compared 
with the standard drug (Clotrimazole) at 5µg/disc concentration level. 
All the synthesized compounds at 100 µg/disc concentrations were shown mild to 
moderate activity against all the screened fungal strains. 
Among the tested fungal strains, all the synthesized compounds at 100μg/disc 
concentration were shown more activity against Aspergillus niger and Trichophyton 
rubrum  with the percentage of inhibition range from 53-93%.  
Among the synthesized compounds, compounds DPN 07, DPN 08 and DPN 15 
shown better antifungal activity than the other synthesized compounds with the 
percentage of inhibition value from 53-93%. Most of the synthesized compounds show 
MIC value at 25 and 50 μg/ml concentration levels.  
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The newly synthesized compounds DPN 07, DPN 08 and DPN 15 were shown MIC 
value at 6.25 and 12.5μg/ml concentration levels, Aspergillus niger, Trichophyton 
rubrum and Candida albicans, Monascus purpureus respectively. 
In-Vitro Anti-Malarial Activity 
The anti-malarial studies were carried out with the randomly selected synthesized 
Flavone derivatives in the concentration 20µg/ml, 40µg/ml, 60µg/ml, 80µg/ml in DMSO 
against Plasmodium falciparum using Candle jar method. Pyremethamine of same 
concentrations was used as standard. The anti-malarial activities of the compounds were 
evaluated by estimation of percentage of inhibition of parasethima at different 
concentration. It could be seen that these newly synthesized derivatives of flavone exhibit 
weak to good anti-malarial activity. Out of the compounds synthesized DPN 08 & DPN 
11 was most potent which exhibit 87.69% inhibition at 80µg/ml concentration. Other 
derivatives (DPN 06, DPN 10 and DPN 12) also showed inhibition more than 80 % i.e. 
(84.61%, 84.61% and 80 %,) respectively. 
In-Vitro Antioxidant Activities 
All newly synthesized compounds (DPN 1-15) were screened for in-vitro anti-
oxidant activity by DPPH, FRAP and ABTS assay method at the concentration of 
10µg/ml, 20µg/ml, 40µg/ml, 60µg/ml, 80µg/ml and 100µg/ml.  DMSO was used as a 
solvent, ascorbic acid was used as a standard for DPPH and ABTS, ferrous sulphate was 
used as a standard for FRAP method.   
DPPH ASSAY: 
 Free radical scavenging capacity of flavone derivatives has been primarily 
attributed to the high reactivity of hydroxyl substituent’s that participate in the 
following reaction. 
Flavone-OH +R
.
           Flavone-O
.
 +RH 
 The result of in-vitro anti oxidant activity by DPPH method indicates that 
compounds  DPN-02, DPN-03, DPN-04, DPN-05, DPN-06, DPN-07, DPN-08, 
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DPN-09, DPN-11, DPN-12 and DPN-13 have significant anti oxidant activity with 
EC50 value 8.57,8.14, 8.88, 8.57, 8.12, 18.21, 18.69, 9.46, 18.69, 9.92 and 8.24 
respectively. 
  As in the case of flavones, the electron-withdrawing or -donating character of the 
substituent’s does not play an  important role  for anti oxidant activity 
ABTS ASSAY: 
 The result of in-vitro anti oxidant activity by ABTS method shows that among the 
screened compounds, compound DPN-01, DPN-07, DPN-08, DPN-10 and DPN-
12 have significant anti oxidant activity with EC50 value 8.41, 8.56, 18.21, 8.47and 
8.27 respectively. The other synthesized compounds showed mild anti oxidant 
activity. The ABTS in-vitro anti oxidant assay method result review that the Schiff 
base synthesized from aldehydes derivatives shows potent anti oxidant activity 
when compared with ketones derivatives. The percentage inhibition values were 
given in the table 6.9 
FRAP ASSAY: 
 The result of in-vitro anti oxidant activity by FRAP method indicates that among 
the screened compounds, compound DPN-02, DPN-03, DPN-10, DPN-11, DPN-
12 and DPN-1 have significant anti oxidant activity with R
2 
value of 0.934, 0.965, 
0.98, 0.978, 0.98, 0.975 near to the standard ferrous sulphate value of 0.995 
indicating that compounds containing substitution of electron donating group 
attach  at the ring imparted significant anti oxidant property to the resulting Schiff 
base containing flavone derivatives. The percentage inhibition values were given 
in the table showed good anti oxidant activity. The R
2
 values were given in the 
table 6.10. 
 
In all the above screened method among the synthesized compounds, Compound 
DPN 12 bearing substituted Hydroxy and methoxy group showed potent anti 
oxidant activity when compared with the standard. 
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IN-VITRO ANTI-CANCER ACTIVITY 
 Four of the newly synthesized compounds (DPN 3, DPN 06, DPN 08 and DPN 
11) were randomly selected and screened for in vitro anti-cancer activity against 
human hepatic carcinoma cell line (HepG2) by MTT assay in DMSO. 
 In-vitro anti-cancer results indicate that they are very weekly cytotoxic effect 
against human hepatic carcinoma cell line (HepG2). 
DOCKING  
 Docking studies of compounds (DPN 02, DPN 06, DPN08, DPN 10, DPN 11, 
DPN 12, DPN13, DPN 14) using pf-DHFR-TS- Plasmodium falciparum 
dihydrofolate reductase-thymidylate synthase (PDB: 1J3I) protein. In which 
the compounds DPN 06, DPN08, DPN 10, DPN 11, DPN 12, DPN 14 having 
docking score -6.07,-9.81,-7.3,-6.9,-6.37, -3.5. 
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SUMMARY AND CONCLUSION: 
 23 compounds were synthesized by two different methods. 
 15 compounds of Schiff base derivatives by conventional method and 8 
compounds of Schiff base derivatives by microwave irradiation method was 
synthesized, purified and characterized by spectral data’s. 
 The homogeneity of the synthesized compounds was monitored by ascending thin 
layer chromatography. 
 Both in the conventional and microwave irradiation methods the same molecule is 
obtained in which the former method took 8 folds of time than the later method. 
The percentage yield obtained was comparatively higher (above 92%) in 
microwave method than the conventional method. 
ANTI-MICROBIAL ACTIVITY 
 Compounds DPN 1-15 (15 compounds) were screened on various bacterial and 
fungal strains. 
Compounds DPN 07, DPN 08 and DPN 11 were found to be more potent anti-
bacterial and DPN 07, DPN 08 and DPN 15 antifungal activity than standard 
ciprofloxacin and Clotrimazole. 
ANTI- MALARIAL ACTIVITY: 
 Compounds DPN 03, DPN 06, DPN 08, DPN 10, DPN 11, DPN 12, DPN 13 and 
DPN 14 (8 compounds) were screened against P.falciparum. 
 Compounds DPN 06, DPN 08, DPN 10, DPN 11 and DPN 12 showed potent 
activity when compared with standard pyremethamine. 
 It was evident from the docking analysis as well as antimalarial evaluation, title 
molecules were disclosed admirable scoring and significant bio-activity. It was 
concluded from docking studies that our molecules were deeply engulfed into the 
inner groove of pf-DHFR-TS active site by making stable ligand receptor posses. 
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ANTI-OXIDANT ACTIVITY 
 The DPPH, FRAP and ABTS in-vitro anti oxidant methods result of the 
synthesized compound review that the electron withdrawing group attached at ring 
Compounds (DPN 12) shows potent activity. 
 
ANTI-CANCER ACTIVITY: 
None of the compound showed potent activity against HepG2 Cell. 
Compound DPN 07, DPN 08, DPN 11 and DPN12 were found to more potent 
compound, so this can be used as lead for further studies. 
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